<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral antiplatelet therapy for acute ischaemic stroke - Minhas, JS - 2022 | Cochrane Library</title> <meta content="Oral antiplatelet therapy for acute ischaemic stroke - Minhas, JS - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000029.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral antiplatelet therapy for acute ischaemic stroke - Minhas, JS - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000029.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000029.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Oral antiplatelet therapy for acute ischaemic stroke" name="citation_title"/> <meta content="Jatinder S Minhas&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Leicester" name="citation_author_institution"/> <meta content="jm591@leicester.ac.uk" name="citation_author_email"/> <meta content="Tamara Chithiramohan&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Leicester" name="citation_author_institution"/> <meta content="Xia Wang" name="citation_author"/> <meta content="University of New South Wales" name="citation_author_institution"/> <meta content="Sam C Barnes" name="citation_author"/> <meta content="University of Leicester" name="citation_author_institution"/> <meta content="Rebecca H Clough" name="citation_author"/> <meta content="University of Leicester" name="citation_author_institution"/> <meta content="Meeriam Kadicheeni" name="citation_author"/> <meta content="University of Leicester" name="citation_author_institution"/> <meta content="Lucy C Beishon&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Leicester" name="citation_author_institution"/> <meta content="Thompson Robinson&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Leicester" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD000029.pub4" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/01/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000029.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000029.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000029.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Aspirin [adverse effects]; *Brain Ischemia [drug therapy]; *Ischemic Stroke; Platelet Aggregation Inhibitors [adverse effects]; Randomized Controlled Trials as Topic; *Stroke [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000029.pub4&amp;doi=10.1002/14651858.CD000029.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6zFwvAqw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000029\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000029\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000029\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000029\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ko","pt","ms","hr","fr","zh_HANT","th","ja","fa","ro"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000029.pub4",title:"Oral antiplatelet therapy for acute ischaemic stroke",firstPublishedDate:"Jan 14, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Stroke Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000029.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000029.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000029.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000029.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000029.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000029.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000029.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000029.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000029.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000029.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6550 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000029.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/full#CD000029-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/full#CD000029-sec-0090"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/full#CD000029-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/full#CD000029-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/full#CD000029-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/full#CD000029-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/full#CD000029-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/full#CD000029-sec-0074"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/appendices#CD000029-sec-0096"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/supinfo/CD000029StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/supinfo/CD000029StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral antiplatelet therapy for acute ischaemic stroke</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="Joint first author"><a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/information#CD000029-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Jatinder S Minhas</a><sup>a</sup></li> <li class="author custom-tooltip" title="Joint first author"><a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/information#CD000029-cr-0005">Tamara Chithiramohan</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/information#CD000029-cr-0006">Xia Wang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/information#CD000029-cr-0007">Sam C Barnes</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/information#CD000029-cr-0008">Rebecca H Clough</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/information#CD000029-cr-0009">Meeriam Kadicheeni</a></li> <li class="author custom-tooltip" title="Joint senior author"><a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/information#CD000029-cr-0010">Lucy C Beishon</a><sup>a</sup></li> <li class="author custom-tooltip" title="Joint senior author"><a href="/cdsr/doi/10.1002/14651858.CD000029.pub4/information#CD000029-cr-0011">Thompson Robinson</a><sup>a</sup></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/information/en#CD000029-sec-0116">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 January 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000029.pub4">https://doi.org/10.1002/14651858.CD000029.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000029-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000029-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000029-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000029-abs-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000029-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD000029-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD000029-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD000029-abs-0016">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000029-abs-0001" lang="en"> <section id="CD000029-sec-0001"> <h3 class="title" id="CD000029-sec-0001">Background</h3> <p>In people with acute ischaemic stroke, platelets become activated and can cause blood clots to form and block an artery in the brain, resulting in damage to part of the brain. Such damage gives rise to the symptoms of stroke. Antiplatelet therapy might reduce the volume of brain damaged by ischaemia and also reduce the risk of early recurrent ischaemic stroke, thereby reducing the risk of early death and improving long‐term outcomes in survivors. However, antiplatelet therapy might also increase the risk of fatal or disabling intracranial haemorrhage. </p> </section> <section id="CD000029-sec-0002"> <h3 class="title" id="CD000029-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of immediate oral antiplatelet therapy (i.e. started as soon as possible and no later than two weeks after stroke onset) in people with acute presumed ischaemic stroke. </p> </section> <section id="CD000029-sec-0003"> <h3 class="title" id="CD000029-sec-0003">Search methods</h3> <p>We searched the Cochrane Stroke Group Trials Register, CENTRAL, MEDLINE Ovid, Embase Ovid, and two trials registers, and performed forward reference/cited reference searching in August 2020. </p> </section> <section id="CD000029-sec-0004"> <h3 class="title" id="CD000029-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) comparing oral antiplatelet therapy (started within 14 days of the stroke) with control in people with definite or presumed ischaemic stroke. </p> </section> <section id="CD000029-sec-0005"> <h3 class="title" id="CD000029-sec-0005">Data collection and analysis</h3> <p>Two review authors independently applied the inclusion criteria and assessed trial quality. For the included trials, they extracted and cross‐checked the data. They assessed risk of bias of each study using the Risk of Bias 1 (RoB1) tool and overall certainty of the evidence for each outcome using the GRADE approach. </p> </section> <section id="CD000029-sec-0006"> <h3 class="title" id="CD000029-sec-0006">Main results</h3> <p>We included 11 studies involving 42,226 participants. Three new trials have been added since the last update (743 participants). As per the previous version of this review, two trials testing aspirin 160 mg to 300 mg once daily, started within 48 hours of onset, contributed 96% of the data. The risk of bias was low. The maximum follow‐up was six months. With treatment, there was a decrease in death or dependency at the end of follow‐up (odds ratio (OR) 0.95, 95% confidence interval (CI) 0.91 to 0.99; 7 RCTs, 42,034 participants; moderate‐certainty evidence). For every 1000 people treated with aspirin, 13 people would avoid death or dependency (number needed to treat for an additional beneficial outcome 79). </p> </section> <section id="CD000029-sec-0007"> <h3 class="title" id="CD000029-sec-0007">Authors' conclusions</h3> <p>Antiplatelet therapy with aspirin 160 mg to 300 mg daily, given orally (or by nasogastric tube or per rectum in people who cannot swallow) and started within 48 hours of onset of presumed ischaemic stroke, significantly decreased death and dependency, and reduced the risk of early recurrent ischaemic stroke without a major risk of early haemorrhagic complications; long‐term outcomes were improved. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000029-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000029-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD000029-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD000029-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000029-abs-0020">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000029-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD000029-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD000029-abs-0018">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD000029-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD000029-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD000029-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/ro#CD000029-abs-0021">Română</a> </li> <li class="section-language"> <a class="" href="full/ru#CD000029-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD000029-abs-0017">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD000029-abs-0015">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000029-abs-0002" lang="en"> <h3>Oral antiplatelet therapy for acute ischaemic stroke</h3> <p><b>Review question</b> </p> <p>We wanted to compare the safety and effectiveness of oral antiplatelet therapy versus placebo or no treatment in people with acute ischaemic stroke to see if oral antiplatelet medicines reduced the number of deaths and improved the long‐term outcomes in survivors. </p> <p><b>Background</b> </p> <p>Most strokes are caused by a sudden blockage of an artery in the brain that is usually due to a blood clot (called an ischaemic stroke). Immediate treatment with antiplatelet medicines such as aspirin may prevent new clots from forming and hence improve recovery after stroke. However, antiplatelet medicines may also cause bleeding in the brain, which could offset any benefits. </p> <p><b>Study characteristics</b> </p> <p>We identified 11 studies, up to August 2020, for inclusion in the review. These studies included 42,226 participants. Three new trials have been added since the last update. As per the previous version of this review, two studies contributed 96% of the data. Most participants in the review were elderly, with a significant proportion over 70 years of age. Males and females were almost equally represented in the trials. There appeared to be some variation in stroke severity among the included trials. The scheduled duration of treatment varied from five days to three months and the scheduled follow‐up period varied from 10 days to six months. </p> <p><b>Key results</b> </p> <p>Aspirin, at a dose of 160 mg to 300 mg daily, started within 48 hours of the onset of stroke symptoms, saved lives and reduced the risk of further stroke occurring in the first two weeks. If treatment was started more than 48 hours after onset but within 14 days, the limited evidence from this review and other external data suggest that aspirin is of benefit even starting at this late stage. Antiplatelet therapy with aspirin 160 mg to 300 mg daily, given orally (or by a tube through the nose and into the stomach or by the rectum in people who cannot swallow) and started within 48 hours of onset of presumed ischaemic stroke, reduced the risk of early recurrent ischaemic stroke without a major risk of early haemorrhagic complications; long‐term outcomes were improved. Almost all the evidence in this review came from trials of aspirin. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence contributing to these results was generally good.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000029-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000029-sec-0090"></div> <h3 class="title" id="CD000029-sec-0091">Implications for practice</h3> <section id="CD000029-sec-0091"> <p> <ul id="CD000029-list-0010"> <li> <p>The review provided strong evidence for the benefits of aspirin 160 mg to 300 mg, given as soon as is practicable (and continued as a once daily dose), in people with suspected acute ischaemic stroke. This evidence applied chiefly to people seen within 48 hours of stroke onset and in whom intracranial haemorrhage had been excluded, or was thought to be clinically unlikely, and had no definite contraindications to aspirin. In people who are unable to swallow safely, aspirin may be given per rectum as a suppository or via a nasogastric tube. </p> </li> <li> <p>The assessment of the safety and efficacy of antiplatelet agents in people with primary intracranial haemorrhage was not the aim of this review. However, it did provide limited evidence on the effects of aspirin in people in whom intracranial haemorrhage had not been ruled out by brain scanning before treatment was started and who subsequently were shown to have had an intracranial haemorrhage. There was no evidence of net harm in such people. Thus, if there is likely to be a delay before computer tomography or magnetic resonance brain scanning can be performed to exclude intracranial haemorrhage it may be reasonable to give aspirin until the scan result is known. If the scan shows intracranial haemorrhage, then aspirin should probably be discontinued. </p> </li> <li> <p>In people who cannot tolerate aspirin, an alternative antiplatelet agent should be considered in the acute stage of stroke, although the evidence for other agents is inadequate at present. </p> </li> <li> <p>This review confirmed the benefit of continuing treatment in hospital, and external evidence supports its continuation after hospital discharge. </p> </li> </ul> </p> </section> <h3 class="title" id="CD000029-sec-0092">Implications for research</h3> <section id="CD000029-sec-0092"> <p> <ul id="CD000029-list-0011"> <li> <p>The overall treatment effect of antiplatelet agents in acute ischaemic stroke is not large and better acute therapies are therefore necessary. The question of whether any particular antiplatelet agent is superior to aspirin 160 mg to 300 mg in the treatment of acute ischaemic stroke remains to be determined, and would require a very large randomised trial to be answered reliably. </p> </li> <li> <p>In people with unstable coronary artery disease, trials have evaluated the addition of low molecular‐weight heparin or another antiplatelet agent (such as a glycoprotein IIb/IIIa inhibitor or clopidogrel) to aspirin. There is a case for such trials to be undertaken in acute ischaemic stroke. There is also a case for further trials of low‐dose subcutaneous heparin (or low‐dose low molecular‐weight heparin) plus aspirin versus aspirin alone in the prevention of poststroke deep vein thrombosis and pulmonary embolism, and in reducing neurological disability from the original or recurrent strokes. Such trials would need to include several 10s of 1000s of participants. </p> </li> <li> <p>Future trials comparing more intense antiplatelet or antithrombotic regimens with aspirin in acute ischaemic stroke will need to include several 10s of 1000s of participants and should also test the effects and interactions during treatments such as intravenous thrombolysis and mechanical thrombectomy. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000029-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000029-sec-0008"></div> <div class="table" id="CD000029-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antiplatelet drug compared to control in acute presumed ischaemic stroke for acute ischaemic stroke</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Antiplatelet drug compared to control in acute presumed ischaemic stroke for acute ischaemic stroke</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> acute ischaemic stroke<br/><b>Setting:</b> secondary care<br/><b>Intervention:</b> antiplatelet drug<br/><b>Comparison:</b> control in acute presumed ischaemic stroke </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with control in acute presumed ischaemic stroke</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with antiplatelet drug</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Death or dependence</b> at end of follow‐up (primary outcome) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>42,034<br/>(7 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 0.95</b><br/>(0.91 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 fewer per 1000<br/>(23 fewer to 2 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Death from any cause</b> during follow‐up </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>41,929<br/>(10 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 0.93</b><br/>(0.87 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 fewer per 1000<br/>(15 fewer to 2 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pulmonary embolism</b> during treatment period </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>41,042<br/>(7 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,e,f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 0.71</b><br/>(0.53 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 fewer per 1000<br/>(2 fewer to 0 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent ischaemic/unknown stroke</b> during treatment period </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>41,652<br/>(9 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 0.79</b><br/>(0.70 to 0.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 fewer per 1000<br/>(9 fewer to 4 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Symptomatic intracranial haemorrhage</b> during treatment period </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>41,652<br/>(9 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c,h,i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 1.18</b><br/>(0.97 to 1.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 more per 1000<br/>(0 fewer to 4 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major extracranial haemorrhage</b> during treatment period </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>41,042<br/>(7 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,e,i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 1.69</b><br/>(1.35 to 2.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 more per 1000<br/>(2 more to 6 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complete recovery from stroke</b> (post hoc) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>40,541<br/>(2 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 1.06</b><br/>(1.01 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 more per 1000<br/>(2 more to 21 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>Peto</b> <b>OR:</b> Peto odds ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>The CAST study included only participants of Chinese ethnicity and contributed almost 50% of the data in the meta‐analysis. Therefore, the results are mainly applicable to a Chinese population.<br/><sup>b</sup>Death or dependence is the primary outcome measure for the majority of acute stroke intervention trials.<br/><sup>c</sup>Two studies were at high risk of bias, for one study there was no information on risk of bias, and for one study the risk of bias was unclear.<br/><sup>d</sup>Studies showed variable results (some increased, reduced or no change in the event). Therefore, results were not consistent between studies, although there was overlap in the confidence intervals and heterogeneity was low (I<sup>2</sup> &lt; 25%).<br/><sup>e</sup>One study was at high risk of bias, one study was at unclear risk of bias, and for one study information on risk of bias was not available.<br/><sup>f</sup>The analysis was based on two small studies and the confidence intervals were wide.<br/><sup>g</sup>Deep vein thrombosis and pulmonary embolism are important complications following acute stroke, but secondary to death or dependence.<br/><sup>h</sup>Recurrent stroke and symptomatic intra‐ or extra‐cranial haemorrhage were a commonly reported outcome measures but are secondary to death or dependence.<br/><sup>i</sup>The confidence intervals were wide, but data were from two large studies.<br/><sup>j</sup>Complete recovery from stroke is an important outcome, reported in the two largest trials in this review, but remains secondary to death or dependence which is the most commonly reported outcome measure. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000029-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000029-sec-0009"></div> <section id="CD000029-sec-0010"> <h3 class="title" id="CD000029-sec-0010">Description of the condition</h3> <p>Stroke is an enormous and serious public health problem. According to the World Health Organization (WHO), 15 million people have stroke worldwide each year. It is also a major cause of death and disability worldwide. Approximately 80% to 87% of all strokes are ischaemic (i.e. due to a blockage of an artery in the brain) in white populations (<a href="./references#CD000029-bbs2-0045" title="JauchEC , SaverJL , Adams HP Jr, BrunoA , ConnorsJJ , DemaerschalkBM , American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2013;44:870-947. [DOI: 10.1161/STR.0b013e318284056a]">Jauch 2013</a>; <a href="./references#CD000029-bbs2-0072" title="WarlowC . Stroke, transient ischaemic attacks, and intracranial venous thrombosis. In: DonaghyM , editors(s). Brain's Diseases of the Nervous System. 11th edition. Oxford (UK): Oxford University Press, 2001:775-896.">Warlow 2001</a>), and about 67% in Asian populations (<a href="./references#CD000029-bbs2-0066" title="TsaiCF , ThomasB , SudlowCL . Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review. Neurology2013;81(3):264-72.">Tsai 2013</a>). </p> </section> <section id="CD000029-sec-0011"> <h3 class="title" id="CD000029-sec-0011">Description of the intervention</h3> <p>Platelets become activated in people with acute ischaemic stroke. This review is focused on oral antiplatelet agents. Oral antiplatelet agents work via different mechanisms to inhibit platelet adhesion and aggregation. The types of drugs include cyclo‐oxygenase inhibitors (e.g. aspirin (acetylsalicylic acid; ASA)), thienopyridine derivatives (e.g. ticlopidine, clopidogrel), phosphodiesterase inhibitors (e.g. dipyridamole, cilostazol), and thromboxane A2 antagonists (e.g. ozagrel). </p> </section> <section id="CD000029-sec-0012"> <h3 class="title" id="CD000029-sec-0012">How the intervention might work</h3> <p>Antiplatelet therapy is effective for long‐term secondary prevention of serious vascular events in people at high risk of vascular disease (<a href="./references#CD000029-bbs2-0019" title="Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ1994;308:81-106.">ATC 1994a</a>; <a href="./references#CD000029-bbs2-0021" title="Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ2002;324:71-86.">ATC 2002</a>; <a href="./references#CD000029-bbs2-0022" title="Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet2009;373:1849-60.">ATC 2009</a>). In people with acute myocardial infarction, starting antiplatelet therapy immediately after the event, and continuing it for one month, avoids about 38 vascular events for every 1000 people treated (<a href="./references#CD000029-bbs2-0019" title="Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ1994;308:81-106.">ATC 1994a</a>; <a href="./references#CD000029-bbs2-0021" title="Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ2002;324:71-86.">ATC 2002</a>). In individuals with ischaemic stroke or transient ischaemic attack (TIA), being on long‐term antiplatelet therapy avoids about 36 serious vascular events for every 1000 people treated for three years (<a href="./references#CD000029-bbs2-0019" title="Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ1994;308:81-106.">ATC 1994a</a>; <a href="./references#CD000029-bbs2-0021" title="Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ2002;324:71-86.">ATC 2002</a>). Platelets are activated in the acute phase of ischaemic stroke, releasing neurotoxic and thrombogenic eicosanoids including thromboxane B2 (<a href="./references#CD000029-bbs2-0068" title="vanKootenF , CiabattoneG , PatronoC , SchmitzPI , vanGijnJ , KoudstaalPJ . Evidence for episodic platelet activation in acute ischaemic stroke. Stroke1994;25:278-81.">van Kooten 1994</a>). </p> <p>Antiplatelet therapy is, therefore, a logical treatment to evaluate in acute ischaemic stroke. It might reduce early deaths and improve outcomes in survivors by reducing the volume of brain damaged by ischaemia and reducing the risk of early recurrent ischaemic stroke and pulmonary embolism (PE) (<a href="./references#CD000029-bbs2-0019" title="Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ1994;308:81-106.">ATC 1994a</a>; <a href="./references#CD000029-bbs2-0020" title="Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ1994;308:235-46.">ATC 1994b</a>). However, antiplatelet therapy could also increase the risk of fatal or disabling intracranial haemorrhage (ICH), thus offsetting any benefits (<a href="./references#CD000029-bbs2-0019" title="Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ1994;308:81-106.">ATC 1994a</a>). However, recent randomised data have suggested that antiplatelets may be safe even after primary intracerebral haemorrhage when risk of recurrent intracerebral haemorrhage is weighed against benefits of preventing occlusive vascular disease (<a href="./references#CD000029-bbs2-0057" title="RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet2019;393(10191):2613-23. [DOI: doi.org/10.1016/S0140-6736(19)30840-2]">RESTART 2019</a>). The initial data were sufficiently promising that two large‐scale trials were undertaken: the International Stroke Trial (<a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>), and the Chinese Acute Stroke Trial (<a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>), which together included over 40,000 participants. These trials provided reliable evidence of the net benefit from aspirin in this setting. As a result, evidence‐based guidelines in Europe, Canada, and USA now recommend aspirin as the standard antithrombotic treatment for acute ischaemic stroke (<a href="./references#CD000029-bbs2-0018" title="GoAS , MozaffarianD , RogerVL , BenjaminEJ , BerryJD , BordenWB , American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation2013;127:e6-e245. [DOI: 10.1161/CIR.0b013e31828124ad]">AHA 2013</a>; <a href="./references#CD000029-bbs2-0017" title="American Heart Association Stroke Council. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2019;50:344-418.">AHA/ASA Guidelines</a>; <a href="./references#CD000029-bbs2-0033" title="Canadian Stroke Network and Heart and Stroke Foundation of Canada. Canadian best practice recommendations for stroke care: update 2010. www.canadianstrokenetwork.ca/ (accessed prior to 24 November 2021).">CSS 2010</a>; <a href="./references#CD000029-bbs2-0038" title="The European Stroke Organisation Executive Committee and the ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovascular Diseases2008;25::457-507. [DOI: 10.1159/000131083]">ESO 2008</a>; <a href="./references#CD000029-bbs2-0045" title="JauchEC , SaverJL , Adams HP Jr, BrunoA , ConnorsJJ , DemaerschalkBM , American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2013;44:870-947. [DOI: 10.1161/STR.0b013e318284056a]">Jauch 2013</a>; <a href="./references#CD000029-bbs2-0056" title="Royal College of Physicians. National Clinical Guidelines for Stroke, Fifth Edition 2016. www.rcplondon.ac.uk/resources/stroke-guidelines (accessed prior to 24 November 2021).">RCP Guideline 2016</a>). </p> <p>Most data relating to orally active antiplatelet agents is derived from trials of aspirin. Data regarding the utility of other single oral antiplatelet agents, including clopidogrel, dipyridamole, or cilostazol, for the treatment of acute stroke are limited (<a href="./references#CD000029-bbs2-0026" title="LeeYS , BaeHJ , KangDW , LeeSH , YuK , ParkJM , et al. Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial. Cerebrovascular Diseases2011;32:65-71. [DOI: 10.1159/000327036]">CAIST 2011</a>; <a href="./references#CD000029-bbs2-0028" title="ChairangsaritP , SithinamsuwanP , NiyasomS , UdommongkolC , NidhinandanaS , SuwantameeJ . Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. Journal of the Medical Association of Thailand2005;88:S148-54.">Chairangsarit 2005</a>; <a href="./references#CD000029-bbs2-0062" title="SuriMF , HusseinHM , AbdelmoulaMM , DivaniAA , QureshiAI . Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience. Medical Science Monitor2008;14:I39-44.">Suri 2008</a>)<i>.</i> Overall, the data do not provide solid evidence about the utility of these antiplatelet agents in the management of people with acute ischaemic stroke. There has been limited experience and no evidence to support the use of ozagrel in the setting of acute stroke (<a href="./references#CD000029-bbs2-0073" title="ZhangJ , YangJ , ChangX , ZhangC , ZhouH , LiuM . Ozagrel for acute ischemic stroke: a meta-analysis of data from randomized controlled trials. Neurological Research2012;34:346-53. [DOI: 10.1179/1743132812Y.0000000022]">Zhang 2012</a>)<i>.</i> Trials have investigated the early use of multiple antiplatelet agents in addition to aspirin in the acute phase of stroke. Early initiation of aspirin plus extended‐release dipyridamole seem to be as safe and effective in preventing disability as later initiation after conventional aspirin monotherapy (<a href="./references#CD000029-bbs2-0037" title="DenglerR , DienerHC , SchwartzA , GrondM , SchumacherH , MachnigT , EARLY Investigators. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial. Lancet Neurology2010;9:159-66. [DOI: 10.1016/S1474-4422(09)70361-8]">EARLY 2010</a>). Ticagrelor did not provide superiority over aspirin and bleeding risk was higher compared to aspirin monotherapy (<a href="./references#CD000029-bbs2-0061" title="JohnstonSC , AmarencoP , AlbersGW , DenisonH , EastonJD , EvansSR , SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. New England Journal of Medicine2016;375(1):35-43.">SOCRATES</a>). However, when ticagrelor and aspirin were combined versus aspirin alone, the risk of the composite of stroke or death within 30 days was lower with the combination (<a href="./references#CD000029-bbs2-0065" title="JohnstonSC , AmarencoP , DenisonH , EvansSR , HimmelmannA , JamesS , THALES Investigators. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. New England Journal of Medicine2020;383(3):207-17.">THALES</a>). Other trials have examined aspirin and clopidogrel combination therapy. The combination was only significantly effective in the immediate high‐risk interval after stroke or TIA (<a href="./references#CD000029-bbs2-0029" title="WangY , WangY , ZhaoX , LiuL , WangD , WangC , CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New England Journal of Medicine2013;369:11-9. [DOI: 10.1056/NEJMoa1215340]">CHANCE 2013</a>; FASTER 2007<i>;</i><a href="./references#CD000029-bbs2-0041" title="HankeyGJ , HackeW , EastonJD , JohnstonSC , MasJL , BrennanDM , CHARISMA Trial Investigators. Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial. International Journal of Stroke2010;41:1679-83. [DOI: 10.1161/STROKEAHA.110.586727]">Hankey 2010</a>). This has been further clarified by recent data from the <a href="./references#CD000029-bbs2-0055" title="POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. New England Journal of Medicine2018;379:215-25.">POINT</a> trial demonstrating greater benefits of recurrent stroke prevention over risks of major bleeding with dual antiplatelet therapy up to 21 days (<a href="./references#CD000029-bbs2-0055" title="POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. New England Journal of Medicine2018;379:215-25.">POINT</a>). Lastly, triple antiplatelet therapy is not recommended in clinical practice due to significant bleeding risk (<a href="./references#CD000029-bbs2-0064" title="BathPM , WoodhouseLJ , AppletonJP , BeridzeM , ChristensenH , DineenRA , TARDIS Investigators. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. Lancet2018;391(10123):850-9.">TARDIS</a>). </p> </section> <section id="CD000029-sec-0013"> <h3 class="title" id="CD000029-sec-0013">Why it is important to do this review</h3> <p>This review is an update of a previously published review in the <i>Cochrane Database of Systematic Reviews</i> of 'Antiplatelet therapy for acute ischaemic stroke' (<a href="./references#CD000029-bbs2-0075" title="SandercockPA , CounsellC , TsengMC , CecconiE . Oral antiplatelet therapy for acute ischaemic stroke. Cochrane Database of Systematic Reviews2014, Issue 3. Art. No: CD000029. [DOI: 10.1002/14651858.CD000029.pub3]">Sandercock 2014</a>). The previous version of this Cochrane review stated that antiplatelet therapy with aspirin is safe and effective when started within 48 hours after stroke. Since then more trials have been published. For this update, as per previous versions, we did not include parenterally administrated antiplatelet agents. Platelet glycoprotein (GP) IIb/IIIa receptor inhibitors are the subject of a separate review (<a href="./references#CD000029-bbs2-0031" title="CicconeA , MottaC , AbrahaI , CozzolinoF , SantilliI . Glycoprotein IIb‐IIIa inhibitors for acute ischaemic stroke. Cochrane Database of Systematic Reviews2014, Issue 3. Art. No: CD005208. [DOI: 10.1002/14651858.CD005208.pub3]">Ciccone 2014</a>). Therefore, we conducted this updated review to assess the efficacy and safety of oral antiplatelet therapy when administered to people with acute ischaemic stroke to provide more up‐to‐date evidence for clinical practice and to identify trials of newer agents. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000029-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000029-sec-0014"></div> <p>To assess the efficacy and safety of immediate oral antiplatelet therapy (i.e. started as soon as possible and no later than two weeks after stroke onset) in people with acute presumed ischaemic stroke. </p> <p>We wished to test the hypotheses that oral antiplatelet therapy:</p> <p> <ul id="CD000029-list-0001"> <li> <p>reduces the risk of a poor outcome (i.e. the risk of death or being dependent on others for activities of daily living) several months after the stroke; </p> </li> <li> <p>reduces the risk of death several months after ischaemic stroke;</p> </li> <li> <p>reduces the risk of deep vein thrombosis (DVT) and PE following ischaemic stroke;</p> </li> <li> <p>reduces the risk of recurrent ischaemic stroke during the scheduled treatment period;</p> </li> <li> <p>may increase the risk of bleeding, and that the incidence of both ICH and major extracranial haemorrhage may be increased during the scheduled treatment period. </p> </li> </ul> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000029-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000029-sec-0015"></div> <section id="CD000029-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000029-sec-0017"> <h4 class="title">Types of studies</h4> <p>We sought to identify all unconfounded randomised controlled trials (RCTs) of early treatment with oral antiplatelet therapy in which treatment allocation was adequately concealed from doctors entering people into the trials. We excluded trials that were not truly random (e.g. alternating or based on date of birth, day of the week, hospital number) or in which allocation to the treatment or control group was not adequately concealed (such as an open random number list) since foreknowledge of treatment allocation might lead to non‐random treatment allocation and consequent bias in the estimation of treatment effects (<a href="./references#CD000029-bbs2-0052" title="Odgaard-JensenJ , VistGE , TimmerA , KunzR , AklEA , SchünemannH , et al. Randomisation to protect against selection bias in healthcare trials. Cochrane Database of Systematic Reviews2011, Issue 4. Art. No: MR000012. [DOI: 10.1002/14651858.MR000012.pub3]">Odgaard‐Jensen 2011</a>). </p> </section> <section id="CD000029-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included all trials that recruited people of any age or sex within two weeks of onset of presumed ischaemic stroke. We excluded trials of antiplatelet therapy after known primary intracerebral or subarachnoid haemorrhage, but included trials that did not adequately differentiate between ischaemic and haemorrhagic stroke by computed tomography (CT) or magnetic resonance (MR) scans prior to randomisation on the basis that 80% to 87% of strokes are ischaemic in predominantly white populations (<a href="./references#CD000029-bbs2-0045" title="JauchEC , SaverJL , Adams HP Jr, BrunoA , ConnorsJJ , DemaerschalkBM , American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2013;44:870-947. [DOI: 10.1161/STR.0b013e318284056a]">Jauch 2013</a>; <a href="./references#CD000029-bbs2-0072" title="WarlowC . Stroke, transient ischaemic attacks, and intracranial venous thrombosis. In: DonaghyM , editors(s). Brain's Diseases of the Nervous System. 11th edition. Oxford (UK): Oxford University Press, 2001:775-896.">Warlow 2001</a>). </p> </section> <section id="CD000029-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We considered all unconfounded trials that compared either a single oral antiplatelet agent or a combination of oral antiplatelet agents with control (placebo or no treatment) as eligible. We excluded studies either involving 'head‐to‐head' direct comparisons of one agent versus another or comparison of one multiple agent regimen versus a different multiple agent regimen (the latter is the subject of a separate review: Kamal 2012). We broadly defined oral antiplatelet agents as any agents whose principal effects were to inhibit platelet adhesion and aggregation. These included: </p> <p> <ul id="CD000029-list-0002"> <li> <p>cyclo‐oxygenase inhibitors (e.g. aspirin);</p> </li> <li> <p>thienopyridine derivatives inhibiting adenosine diphosphate (ADP) receptors (e.g. ticlopidine, clopidogrel); </p> </li> <li> <p>phosphodiesterase inhibitors (e.g. dipyridamole, cilostazol);</p> </li> <li> <p>thromboxane A2 antagonists (e.g. ozagrel).</p> </li> </ul> </p> <p>For this update, we excluded parenterally administrated antiplatelet agents. GP IIb/IIIa receptor inhibitors are the focus of a separate review (<a href="./references#CD000029-bbs2-0031" title="CicconeA , MottaC , AbrahaI , CozzolinoF , SantilliI . Glycoprotein IIb‐IIIa inhibitors for acute ischaemic stroke. Cochrane Database of Systematic Reviews2014, Issue 3. Art. No: CD005208. [DOI: 10.1002/14651858.CD005208.pub3]">Ciccone 2014</a>). </p> <p>We did not include agents with multiple modes of action including some antiplatelet activity (e.g. piracetam, prostacyclin, pentoxifylline), and some of these agents have been evaluated in other Cochrane systematic reviews (<a href="./references#CD000029-bbs2-0024" title="BathPM . Prostacyclin and analogues for acute ischaemic stroke. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD000177. [DOI: 10.1002/14651858.CD000177.pub2]">Bath 2004a</a>; <a href="./references#CD000029-bbs2-0025" title="BathPM , Bath-HextallFJ . Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD000162. [DOI: 10.1002/14651858.CD000162.pub2]">Bath 2004b</a>; <a href="./references#CD000029-bbs2-0059" title="RicciS , CelaniMG , CantisaniTA , RighettiE . Piracetam for acute ischaemic stroke. Cochrane Database of Systematic Reviews2012, Issue 9. Art. No: CD000419. [DOI: 10.1002/14651858.CD000419.pub3]">Ricci 2012</a>). </p> </section> <section id="CD000029-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We examined death and dependency outcomes at the end of the follow‐up period for each study. In addition, we examined recurrent ischaemic/unknown stroke, symptomatic ICH, any recurrent stroke/ICH, and major ICH. </p> <section id="CD000029-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD000029-list-0003"> <li> <p>Death or dependence on help from other people for activities of daily living at least one month after their stroke (death or dependence at end of follow‐up). Many people regard this as the most important outcome since the aim of treatment should not only be to prevent death but also to prevent serious disability in survivors. The minimum interval of one month was used to allow time for recovery from the initial stroke. </p> </li> </ul> </p> </section> <section id="CD000029-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD000029-list-0004"> <li> <p>Death or dependence during the scheduled follow‐up period (as defined by a validated scale or questionnaire, e.g. modified Rankin Scale ≥ 3). </p> </li> <li> <p>Death from any cause during the scheduled treatment period (generally shorter than the scheduled follow‐up period). </p> </li> <li> <p>Death from any cause during the scheduled follow‐up period (generally considered to be greater than one month after the stroke). </p> </li> <li> <p>DVT: objective evidence of DVT detected by the systematic use of imaging techniques such as iodine 125 fibrinogen scanning (I<sup>125</sup> scan), ultrasound of the leg, plethysmography, or X‐ray contrast venography in all participants during the scheduled treatment period (these methods detected both clinically suspected and silent DVTs, the outcome was therefore 'symptomatic or asymptomatic DVT'. Screening of participants by clinical observation alone was not considered adequate). </p> </li> <li> <p>PE: had at least one confirmed symptomatic PE diagnosed by radiological imaging (ventilation‐perfusion scan or CT pulmonary angiogram (CTPA), or at autopsy (symptomatic or not) within the scheduled treatment period. </p> </li> <li> <p>Recurrent stroke during the treatment period that was either definitely ischaemic (haemorrhage excluded by CT or MR scan or autopsy) or of unknown type (no CT or MR scan or autopsy performed). </p> </li> <li> <p>Symptomatic intracranial (intracerebral and extracerebral) haemorrhage, including symptomatic haemorrhagic transformation of the cerebral infarct, during the scheduled treatment period (the haemorrhage must have been confirmed by CT (or MR) scanning after clinical deterioration, or by autopsy). </p> </li> <li> <p>Recurrent stroke (either of ischaemic or unknown type) or symptomatic ICH during the treatment period. </p> </li> <li> <p>Major extracranial haemorrhage during the scheduled treatment period (the definition of major haemorrhage was usually taken from the original article but if none was given it was defined as any fatal bleed, or bleeding severe enough to require transfusion or operation); </p> </li> <li> <p>Complete recovery from stroke.</p> </li> </ul> </p> <p>Note, at a prior update, the final outcome was a post‐hoc analysis, and we acknowledge that the addition of post‐hoc data is subject to selection bias. However, at the time, two trials reported data on the number of participants who had made a complete recovery from their stroke, an important functional outcome that was not a widely reported outcome in stroke trials when the protocol for the earlier version of this review was written (<a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>; <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>). With the report of the effects of thrombolysis on increasing the proportion of people who recover completely from their stroke (e.g. the NINDS trial of tissue plasminogen activator (<a href="./references#CD000029-bbs2-0051" title="The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischaemic stroke. New England Journal of Medicine1995;333:1581-7.">NINDS 1995</a>)), it seemed reasonable to include this outcome here with allowance for its post‐hoc nature. </p> </section> </section> </section> <section id="CD000029-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>See the methods for the Cochrane Stroke Group Specialised register (<a href="http://www.dcn.ed.ac.uk/csrg/entity/searchmethods.pdf" target="_blank">www.dcn.ed.ac.uk/csrg/entity/searchmethods.pdf</a>). We searched for trials in all languages and arranged translation of relevant papers published in languages other than English. </p> <section id="CD000029-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The most recent search was on 24 August 2020. We searched the Cochrane Stroke Group Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library, 2020, Issue 7) (<a href="./appendices#CD000029-sec-0097">Appendix 1</a>), MEDLINE Ovid (last searched 24 August 2020) (<a href="./appendices#CD000029-sec-0098">Appendix 2</a>), Embase Ovid (last searched 24 August 2020) (<a href="./appendices#CD000029-sec-0099">Appendix 3</a>), US National Institutes of Health Ongoing Trials Register (<a href="https://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a>), WHO International Clinical Trials Registry Platform (ICTRP), and forward reference/cited reference searching. </p> <p>We developed the search strategies for CENTRAL, MEDLINE Ovid, and Embase Ovid with the help of the Cochrane Stroke Group Information Specialist and we updated the search strategies to include any new vocabulary terms and drug names. </p> </section> <section id="CD000029-sec-0025"> <h4 class="title">Searching other resources</h4> <p>In 1998, the authors at the time searched the registers of the Antiplatelet Trialists' Collaboration (<a href="./references#CD000029-bbs2-0019" title="Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ1994;308:81-106.">ATC 1994a</a>; <a href="./references#CD000029-bbs2-0020" title="Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ1994;308:235-46.">ATC 1994b</a>) and MedStrategy (<a href="./references#CD000029-bbs2-0048" title="DickE . Stroke: a Focus of Opportunity. St Louis (MO): MedStrategy, 1995.">MedStrategy 1995</a>). They contacted the following pharmaceutical companies who marketed antiplatelet agents for details of any trials, particularly unpublished ones: Roussel‐Uclaf (defibrotide), Syntex and Sanofi Winthrop (ticlopidine), Otsuka (cilostazol), Eisai (satigrel), Tokyo Tanebe Seiyaku (sarpolgrelate), Kanebo (KBT 3022), and Takeda Chemical Company (isbogrel). For this version of the review, we did not update the previous searches of the Antiplatelet Trialists' Collaboration register (no longer available), MedStrategy, or make any further contact with pharmaceutical companies. However, we did contact authors of newly included studies for any additional unpublished data. One group responded with additional data that was not relevant to the immediate question of this review (<a href="./references#CD000029-bbs2-0011" title="ZhaoY , YangW , TanZ , WangW , XiaoW , ZengJ , et al. Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial. Stroke and Vascular Neurology2017;2:e000072. ">Zhao 2017</a>). </p> </section> </section> <section id="CD000029-sec-0026"> <h3 class="title" id="CD000029-sec-0026">Data collection and analysis</h3> <p>The review authors of this update performed data collection and analysis as per Cochrane guidelines without deviation from the planned protocol. </p> <section id="CD000029-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors operating in pairs (TC and SB formed the first pair and MK and RC formed the second pair) read the titles, abstracts, and keywords of all records identified from the searches of the electronic bibliographic databases and excluded studies that were clearly irrelevant. JM and LB arbitrated disagreements at the screening stage. We obtained the full texts of the remaining studies and LB and JM selected trials for inclusion based on our defined criteria. The two review authors resolved any disagreements by discussion. </p> </section> <section id="CD000029-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>For each version of the review, two review authors (TC and SB) independently extracted the data on methods, participants, interventions, outcomes, and results, and recorded the information on a data extraction form. We sought data on the number of participants with each outcome event by allocated treatment group, irrespective of compliance and whether or not the participant was subsequently deemed ineligible or otherwise excluded from treatment or follow‐up, to allow an intention‐to‐treat analysis. We also sought data on whether CT or MR scanning was performed prior to randomisation. The same two review authors cross‐checked all extracted data and resolved any disagreements by discussion. If any of the above data were unavailable from the publications, we sought further information by contacting the study authors. </p> </section> <section id="CD000029-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (TC and LB) independently assessed risk of bias using Cochrane's tool for assessing risk of bias (RoB1) (<a href="./references#CD000029-bbs2-0042" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We resolved disagreements through discussion with all review authors. The RoB1 tool consists of seven categories: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. We have included the RoB1 tool and its components in <a href="./appendices#CD000029-sec-0100">Appendix 4</a>. We classified risk of bias as low, high, or unclear, according to guidance produced on using the tool and we have included a narrative summary of the number of studies in each of these categories for each domain (<a href="./references#CD000029-bbs2-0042" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> </section> <section id="CD000029-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated Peto odds ratios (ORs), that is the ratio of the odds of an outcome among treatment‐allocated participants to the corresponding odds amongst controls) with 95% confidence intervals (CI), using Review Manager 5 (<a href="./references#CD000029-bbs2-0058" title="Review Manager (RevMan). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> </section> <section id="CD000029-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>There were no specific unit of analysis issues.</p> </section> <section id="CD000029-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>If any data were not available from the publications, we sought further information from the authors or the relevant pharmaceutical company. When data were missing and could not be derived, we used the published analysis. </p> </section> <section id="CD000029-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the extent of heterogeneity between trial results using the I<sup>2</sup> statistic, which measures the percentage of the variability in effect estimates attributable to heterogeneity rather than sampling error (<a href="./references#CD000029-bbs2-0043" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1.0 (updated March 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Higgins 2020</a>). We considered a value greater than 50% as substantial heterogeneity. </p> </section> <section id="CD000029-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed trials for selective outcome reporting and presented the results as risk of bias tables. We assessed publication bias for the primary outcome and for death within the scheduled treatment period using funnel plots. </p> </section> <section id="CD000029-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We calculated ORs with 95% CIs using the Peto fixed‐effect method (<a href="./references#CD000029-bbs2-0019" title="Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ1994;308:81-106.">ATC 1994a</a>) in Review Manager 5 (<a href="./references#CD000029-bbs2-0058" title="Review Manager (RevMan). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We also calculated the number needed to treat for an additional beneficial outcome (NNTB) and the number of events avoided per 1000 people treated for each outcome if the result was statistically significant. We performed these calculations using the online calculator provided by the Cochrane Stroke Group at <a href="http://www.dcn.ed.ac.uk/csrg/entity/entity_NNT2.asp" target="_blank">www.dcn.ed.ac.uk/csrg/entity/entity_NNT2.asp</a>. The control event rate applied was based on the mean of the relevant control event rates in <a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a> and <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>. </p> </section> <section id="CD000029-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We prespecified the following subgroup analyses for the primary outcome of this review.</p> <p> <ul id="CD000029-list-0005"> <li> <p>Type of oral antiplatelet agent used.</p> </li> <li> <p>Trials in which all participants had intracerebral haemorrhage excluded by CT or MR scanning prior to trial randomisation. </p> </li> <li> <p>Trials in which participants were recruited within 48 hours of their stroke.</p> </li> </ul> </p> <p>We performed an additional post‐hoc subgroup analysis among participants with intracerebral haemorrhages inadvertently randomised in the trials. Two trials included a number of participants who did not have a CT scan until after randomisation (<a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>; <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>). Data on those participants in whom the diagnosis of the initial event leading to randomisation was haemorrhagic stroke and who were dead or dependent at follow‐up were reported in the IST publication (<a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>), and were kindly supplied on request from the CAST trial (<a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>). </p> </section> <section id="CD000029-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We planned several prespecified sensitivity analyses limited to the primary outcome (death or dependency) of the review, including: </p> <p> <ul id="CD000029-list-0006"> <li> <p>only trials with adequate concealment of randomisation;</p> </li> <li> <p>only trials with blinding of participants, personnel, and outcome assessment;</p> </li> <li> <p>only trials at low risk of bias due to completeness of follow‐up.</p> </li> </ul> </p> <p>In the sensitivity analysis, we compared two ORs by assessing whether the difference in the natural logarithms of the two ORs (lnOR) was significantly different from zero using a normal approximation. The variance of each lnOR was estimated as the reciprocal of the variance of the O‐E statistic given in <a href="./references#CD000029-bbs2-0058" title="Review Manager (RevMan). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>. </p> <p>Following analysis of the available evidence it became apparent that three of the prespecified analyses (trials in which participants were randomised within 48 hours, trials with adequate concealment of randomisation, and trials with CT scans prior to randomisation) were inappropriate; this is explained in the <a href="./full#CD000029-sec-0039">Results</a> section. </p> </section> <section id="CD000029-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We assessed the overall certainty of the evidence for each outcome using the GRADE approach (<a href="./references#CD000029-bbs2-0060" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>). We assessed the following factors when deciding whether to downgrade or upgrade the certainty of the evidence for each outcome. </p> <p>Downgrade:</p> <p> <ul id="CD000029-list-0007"> <li> <p>risk of bias;</p> </li> <li> <p>inconsistency;</p> </li> <li> <p>indirectness;</p> </li> <li> <p>imprecision;</p> </li> <li> <p>publication bias.</p> </li> </ul> </p> <p>Upgrade:</p> <p> <ul id="CD000029-list-0008"> <li> <p>large effect;</p> </li> <li> <p>dose–response gradient;</p> </li> <li> <p>plausible confounding effect.</p> </li> </ul> </p> <p>We downgraded the evidence for each outcome by one level where there was a serious limitation, and by two factors where there was a very serious limitation. Our review included only RCTs and so were considered high certainty prior to downgrading. We categorised studies as high, moderate, low, or very low certainty based on these domains. We prepared a summary of findings table using GRADEpro (<a href="./references#CD000029-bbs2-0040" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), (accessed 24 February 2021). Available at gradepro.org.">GRADEpro GDT</a>) and following recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000029-bbs2-0043" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1.0 (updated March 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Higgins 2020</a>). Two review authors (LB and TC) independently decided GRADE assessments and resolved disagreements by discussion. </p> <p>We assessed the following outcomes in the summary of findings table:</p> <p> <ul id="CD000029-list-0009"> <li> <p>death or dependence at end of follow‐up;</p> </li> <li> <p>death from any cause during follow‐up;</p> </li> <li> <p>confirmed symptomatic PE diagnosed during life, or at autopsy (symptomatic or not) within the scheduled treatment period; </p> </li> <li> <p>recurrent stroke during treatment period;</p> </li> <li> <p>symptomatic ICH during treatment period;</p> </li> <li> <p>major extracranial haemorrhage during treatment period;</p> </li> <li> <p>complete recovery from stroke.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000029-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000029-sec-0039"></div> <section id="CD000029-sec-0040"> <h3 class="title">Description of studies</h3> <p>Randomised trials comparing oral antiplatelet therapy (started within 14 days of the stroke) with control in people with definite or presumed ischaemic stroke. </p> <section id="CD000029-sec-0041"> <h4 class="title">Results of the search</h4> <p>We identified 15,085 records from the electronic searches. After eliminating duplicates and non‐relevant studies from the titles and abstracts, we selected 145 possibly relevant studies. After examining the abstracts, or in some cases the full papers, 129 records did not meet the eligibility criteria for the following reasons: previously identified studies, non‐randomised studies, not of an oral antiplatelet therapy, not acute stroke therapy, no control group, an ongoing study, parenteral replacement used, or multiple antiplatelet agents used (the latter are reviewed in a separate Cochrane Review (Kamal 2012)). This process left 16 potentially relevant studies. Of these, five did not fulfil all the inclusion criteria and are listed in the <a href="./references#CD000029-sec-0123" title="">Characteristics of excluded studies</a> table. We included three new studies (<a href="./references#CD000029-bbs2-0003" title="Di CesareF , MancusoJ , WoodwardP , BednarMM , LoudonPT . Phosphodiesterase-5 inhibitor PF-03049423 effect on stroke recovery: a double-blind, placebo-controlled randomized clinical trial. Journal of Stroke and Cerebrovascular Diseases2016;25:642-9. ">Di Cesare 2016</a>; <a href="./references#CD000029-bbs2-0005" title="KhatriP , KleindorferDO , DevlinT , SawyerRN , StarrM , MejillaJ , et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits. JAMA2018;320:156-66. ">Khatri 2018</a>; <a href="./references#CD000029-bbs2-0011" title="ZhaoY , YangW , TanZ , WangW , XiaoW , ZengJ , et al. Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial. Stroke and Vascular Neurology2017;2:e000072. ">Zhao 2017</a>). A PRISMA flowchart of study selection is shown in <a href="#CD000029-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD000029-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram." data-id="CD000029-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> </div> </section> <section id="CD000029-sec-0042"> <h4 class="title">Included studies</h4> <p>We included 11 studies involving 42,226 participants (see <a href="./references#CD000029-sec-0122" title="">Characteristics of included studies</a> table). One of the included trials (53 participants) remains unpublished (<a href="./references#CD000029-bbs2-0009" title="TurpieAG , DobkinB , McKennaR . A trial of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 1983.001.6.188)1983. ">Turpie 1983</a>). Most participants in the review were elderly, with a significant proportion of participants over 70 years of age. For example, 61% of participants enrolled in the International Stroke Trial were aged 70 years or older (<a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>). Males and females were almost equally represented in the trials. </p> <section id="CD000029-sec-0043"> <h5 class="title">Antiplatelet regimens tested</h5> <p>Two studies contributed 96% of the data (<a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>; <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>). <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a> was an open‐treatment, blinded outcome study with a factorial design; participants were allocated to 14 days of treatment with aspirin 300 mg, heparin, both, or neither; that is, the trial tested the effects of aspirin in the presence and absence of heparin (and vice versa) (<a href="./references#CD000029-bbs2-0044" title="International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data and outcome in 984 randomised patients in the pilot study. Journal of Neurology, Neurosurgery, and Psychiatry1996;60:371-6.">IST 1996</a>). <a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a> was a double‐blind randomised trial of one month's treatment with either aspirin 160 mg or matching placebo. In <a href="./references#CD000029-bbs2-0006" title="Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet1995;346:1509-14. ">MAST‐I 1995</a> (a factorial trial of streptokinase and aspirin involving 309 participants), only those participants randomised to aspirin alone and the no treatment group were included in this review as there was a significant interaction between aspirin and streptokinase which invalidated the aspirin plus streptokinase versus streptokinase alone comparison. <a href="./references#CD000029-bbs2-0005" title="KhatriP , KleindorferDO , DevlinT , SawyerRN , StarrM , MejillaJ , et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits. JAMA2018;320:156-66. ">Khatri 2018</a> randomised participants to either oral aspirin and an intravenous (IV) placebo or oral placebo and IV alteplase. Other antiplatelet regimens compared with control were: aspirin (<a href="./references#CD000029-bbs2-0008" title="Rödén-Jüllig Å, BrittonM , MalmkvistK , LeijdB . Aspirin in the prevention of progressing stroke: a randomized controlled study. Journal of Internal Medicine2003;254:584-90. ">Rödén‐Jüllig 2003</a>), ticlopidine (<a href="./references#CD000029-bbs2-0002" title="CiuffettiG , AisaG , MercuriM , LombardiniR , PaltricciaR , NeriC , et al. Effects of ticlopidine on the neurologic outcome and the hemorheologic pattern in the postacute phase of ischemic stroke: a pilot study. Angiology1990;41:505-11. ">Ciuffetti 1990</a>; <a href="./references#CD000029-bbs2-0009" title="TurpieAG , DobkinB , McKennaR . A trial of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 1983.001.6.188)1983. ">Turpie 1983</a>; <a href="./references#CD000029-bbs2-0010" title="UtsumiH . Evaluation of utility of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 001.6.128)1984. ">Utsumi 1988</a>), clopidogrel loading dose (<a href="./references#CD000029-bbs2-0011" title="ZhaoY , YangW , TanZ , WangW , XiaoW , ZengJ , et al. Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial. Stroke and Vascular Neurology2017;2:e000072. ">Zhao 2017</a>), PF‐03049423 (<a href="./references#CD000029-bbs2-0003" title="Di CesareF , MancusoJ , WoodwardP , BednarMM , LoudonPT . Phosphodiesterase-5 inhibitor PF-03049423 effect on stroke recovery: a double-blind, placebo-controlled randomized clinical trial. Journal of Stroke and Cerebrovascular Diseases2016;25:642-9. ">Di Cesare 2016</a>), and aspirin plus dipyridamole (<a href="./references#CD000029-bbs2-0007" title="PinceJ . Thromboses Veineuses des Membres Inferieures et Embolies Pulmonaires au Cours des Accidents Vasculaires Cerebraux. A Propos d'un Essai Comparatif de Traitment Preventif [these pour le Doctorat d'Etat en Medicine]. Toulouse (France): Universite Paul Sabatier, 1981. ">Pince 1981</a>). </p> </section> <section id="CD000029-sec-0044"> <h5 class="title">Time window for inclusion</h5> <p>Trials included participants randomised within six hours (<a href="./references#CD000029-bbs2-0006" title="Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet1995;346:1509-14. ">MAST‐I 1995</a>), 12 hours (<a href="./references#CD000029-bbs2-0002" title="CiuffettiG , AisaG , MercuriM , LombardiniR , PaltricciaR , NeriC , et al. Effects of ticlopidine on the neurologic outcome and the hemorheologic pattern in the postacute phase of ischemic stroke: a pilot study. Angiology1990;41:505-11. ">Ciuffetti 1990</a>), 24 to 78 hours (<a href="./references#CD000029-bbs2-0003" title="Di CesareF , MancusoJ , WoodwardP , BednarMM , LoudonPT . Phosphodiesterase-5 inhibitor PF-03049423 effect on stroke recovery: a double-blind, placebo-controlled randomized clinical trial. Journal of Stroke and Cerebrovascular Diseases2016;25:642-9. ">Di Cesare 2016</a>),48 hours (<a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>; <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>, <a href="./references#CD000029-bbs2-0011" title="ZhaoY , YangW , TanZ , WangW , XiaoW , ZengJ , et al. Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial. Stroke and Vascular Neurology2017;2:e000072. ">Zhao 2017</a>), 72 hours (<a href="./references#CD000029-bbs2-0008" title="Rödén-Jüllig Å, BrittonM , MalmkvistK , LeijdB . Aspirin in the prevention of progressing stroke: a randomized controlled study. Journal of Internal Medicine2003;254:584-90. ">Rödén‐Jüllig 2003</a>), or six days (<a href="./references#CD000029-bbs2-0007" title="PinceJ . Thromboses Veineuses des Membres Inferieures et Embolies Pulmonaires au Cours des Accidents Vasculaires Cerebraux. A Propos d'un Essai Comparatif de Traitment Preventif [these pour le Doctorat d'Etat en Medicine]. Toulouse (France): Universite Paul Sabatier, 1981. ">Pince 1981</a>) of stroke onset. In two trials, the formal entry criterion was a stroke within the previous four weeks (<a href="./references#CD000029-bbs2-0009" title="TurpieAG , DobkinB , McKennaR . A trial of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 1983.001.6.188)1983. ">Turpie 1983</a>; <a href="./references#CD000029-bbs2-0010" title="UtsumiH . Evaluation of utility of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 001.6.128)1984. ">Utsumi 1988</a>), but, as most participants were entered within two weeks, we included them in this review. Data on only those participants entered within two weeks were not available from the authors or the pharmaceutical company. </p> </section> <section id="CD000029-sec-0045"> <h5 class="title">Exclusion criteria</h5> <p>The two main trials in the review did not precisely specify exclusion criteria as they used the uncertainty principle, but suggested that these might include participants thought to be at high risk of adverse effects (e.g. clotting disorders, hepatic or renal failure) or those with a small likelihood of worthwhile benefit (<a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>; <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>). </p> </section> <section id="CD000029-sec-0046"> <h5 class="title">Computer tomography scanning</h5> <p>Three trials adequately excluded people with intracerebral haemorrhage by CT scanning all possible participants before entry into the trial (<a href="./references#CD000029-bbs2-0002" title="CiuffettiG , AisaG , MercuriM , LombardiniR , PaltricciaR , NeriC , et al. Effects of ticlopidine on the neurologic outcome and the hemorheologic pattern in the postacute phase of ischemic stroke: a pilot study. Angiology1990;41:505-11. ">Ciuffetti 1990</a>; <a href="./references#CD000029-bbs2-0006" title="Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet1995;346:1509-14. ">MAST‐I 1995</a>; <a href="./references#CD000029-bbs2-0008" title="Rödén-Jüllig Å, BrittonM , MalmkvistK , LeijdB . Aspirin in the prevention of progressing stroke: a randomized controlled study. Journal of Internal Medicine2003;254:584-90. ">Rödén‐Jüllig 2003</a>). Three trials adequately excluded people with intracerebral haemorrhage by including people with confirmed cerebral infarction on either a CT or MR scan (<a href="./references#CD000029-bbs2-0003" title="Di CesareF , MancusoJ , WoodwardP , BednarMM , LoudonPT . Phosphodiesterase-5 inhibitor PF-03049423 effect on stroke recovery: a double-blind, placebo-controlled randomized clinical trial. Journal of Stroke and Cerebrovascular Diseases2016;25:642-9. ">Di Cesare 2016</a>; <a href="./references#CD000029-bbs2-0005" title="KhatriP , KleindorferDO , DevlinT , SawyerRN , StarrM , MejillaJ , et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits. JAMA2018;320:156-66. ">Khatri 2018</a>; <a href="./references#CD000029-bbs2-0011" title="ZhaoY , YangW , TanZ , WangW , XiaoW , ZengJ , et al. Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial. Stroke and Vascular Neurology2017;2:e000072. ">Zhao 2017</a>). Two trials performed a CT scan in almost all participants; in these trials, clinicians had to have a low suspicion of ICH prior to randomisation (<a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>; <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>). In <a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>, 87% had a CT prior to randomisation; by discharge this number had risen to 94%. In <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>, 67% were scanned before randomisation and 29% after randomisation, so that overall 96% of participants were scanned. Two trials performed no CT scans (<a href="./references#CD000029-bbs2-0007" title="PinceJ . Thromboses Veineuses des Membres Inferieures et Embolies Pulmonaires au Cours des Accidents Vasculaires Cerebraux. A Propos d'un Essai Comparatif de Traitment Preventif [these pour le Doctorat d'Etat en Medicine]. Toulouse (France): Universite Paul Sabatier, 1981. ">Pince 1981</a>; <a href="./references#CD000029-bbs2-0009" title="TurpieAG , DobkinB , McKennaR . A trial of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 1983.001.6.188)1983. ">Turpie 1983</a>), and in <a href="./references#CD000029-bbs2-0010" title="UtsumiH . Evaluation of utility of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 001.6.128)1984. ">Utsumi 1988</a> the use of CT scanning was uncertain. As a result of the variable use of prerandomisation CT scanning, some people with intracerebral haemorrhage were inadvertently entered in the trials and these were included in the main analyses of this review. This may have biased the results against antiplatelet agents, although this is unlikely given the relatively small numbers of participants involved. Furthermore, the inclusion of these people may actually make the conclusions of the review more broadly applicable, since some hospitals admitting people with acute stroke do not have access to CT scanning and so acute treatment may have to be started without definite knowledge of the pathological type of stroke. </p> </section> <section id="CD000029-sec-0047"> <h5 class="title">Stroke severity at entry</h5> <p>There appeared to be some variation in stroke severity among the included trials. For example, in the control group of <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a> early death was recorded as 9%, but was only 4% in <a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>, even though <a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a> assessed participants at four weeks versus two weeks for <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>. <a href="./references#CD000029-bbs2-0008" title="Rödén-Jüllig Å, BrittonM , MalmkvistK , LeijdB . Aspirin in the prevention of progressing stroke: a randomized controlled study. Journal of Internal Medicine2003;254:584-90. ">Rödén‐Jüllig 2003</a> used a Scandinavian Stroke Supervision Scale score of one point or more as the inclusion criterion. Alternatively, <a href="./references#CD000029-bbs2-0005" title="KhatriP , KleindorferDO , DevlinT , SawyerRN , StarrM , MejillaJ , et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits. JAMA2018;320:156-66. ">Khatri 2018</a> only included people with deficits judged not to be clearly disabling at presentation. </p> </section> <section id="CD000029-sec-0048"> <h5 class="title">Scheduled duration of trial treatment</h5> <p>The scheduled duration of treatment varied from five days (<a href="./references#CD000029-bbs2-0008" title="Rödén-Jüllig Å, BrittonM , MalmkvistK , LeijdB . Aspirin in the prevention of progressing stroke: a randomized controlled study. Journal of Internal Medicine2003;254:584-90. ">Rödén‐Jüllig 2003</a>), to three months (<a href="./references#CD000029-bbs2-0010" title="UtsumiH . Evaluation of utility of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 001.6.128)1984. ">Utsumi 1988</a>). The scheduled follow‐up period varied from 10 days (<a href="./references#CD000029-bbs2-0007" title="PinceJ . Thromboses Veineuses des Membres Inferieures et Embolies Pulmonaires au Cours des Accidents Vasculaires Cerebraux. A Propos d'un Essai Comparatif de Traitment Preventif [these pour le Doctorat d'Etat en Medicine]. Toulouse (France): Universite Paul Sabatier, 1981. ">Pince 1981</a>), to six months (<a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>; <a href="./references#CD000029-bbs2-0006" title="Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet1995;346:1509-14. ">MAST‐I 1995</a>). </p> </section> <section id="CD000029-sec-0049"> <h5 class="title">Measures of outcome</h5> <p>Clinically important outcomes were poorly reported in the smaller trials. Seven studies evaluated death or dependence at the end of follow‐up (see <a href="./full#CD000029-tbl-0001">summary of findings Table 1</a>). Most trials used comparable definitions of dependence. They included: the modified Rankin Disability Scale (three or greater) (<a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>; <a href="./references#CD000029-bbs2-0006" title="Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet1995;346:1509-14. ">MAST‐I 1995</a>; <a href="./references#CD000029-bbs2-0011" title="ZhaoY , YangW , TanZ , WangW , XiaoW , ZengJ , et al. Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial. Stroke and Vascular Neurology2017;2:e000072. ">Zhao 2017</a>); and needing help from another person with daily activities (<a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>). For <a href="./references#CD000029-bbs2-0008" title="Rödén-Jüllig Å, BrittonM , MalmkvistK , LeijdB . Aspirin in the prevention of progressing stroke: a randomized controlled study. Journal of Internal Medicine2003;254:584-90. ">Rödén‐Jüllig 2003</a>, we used 'living in an institution' as equivalent to being dependent. Three trials used validated scales (<a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a> used <a href="./references#CD000029-bbs2-0023" title="BamfordJ , SandercockP , WarlowC , SlatteryJ . Inter-observer agreement for the assessment of handicap in stroke patients. Stroke1989;20:8.">Bamford 1989</a>; <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a> used <a href="./references#CD000029-bbs2-0036" title="DennisM , WellwoodI , WarlowC . Are simple questions a valid measure of outcome after stroke?Cerebrovascular Diseases1997;7:22-7.">Dennis 1997</a>; <a href="./references#CD000029-bbs2-0006" title="Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet1995;346:1509-14. ">MAST‐I 1995</a> used <a href="./references#CD000029-bbs2-0027" title="CandeliseL , PinardiG , AritzuE , MusiccoM . Telephone interview for stroke outcome assessment. Cerebrovascular Diseases1994;4:341-3.">Candelise 1994</a>). The primary outcome of two trials was favourable functional outcome, defined as modified Rankin Disability Scale less than 2 (<a href="./references#CD000029-bbs2-0003" title="Di CesareF , MancusoJ , WoodwardP , BednarMM , LoudonPT . Phosphodiesterase-5 inhibitor PF-03049423 effect on stroke recovery: a double-blind, placebo-controlled randomized clinical trial. Journal of Stroke and Cerebrovascular Diseases2016;25:642-9. ">Di Cesare 2016</a>) or less than 1 (<a href="./references#CD000029-bbs2-0005" title="KhatriP , KleindorferDO , DevlinT , SawyerRN , StarrM , MejillaJ , et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits. JAMA2018;320:156-66. ">Khatri 2018</a>). In two trials, the primary outcome was DVT (<a href="./references#CD000029-bbs2-0007" title="PinceJ . Thromboses Veineuses des Membres Inferieures et Embolies Pulmonaires au Cours des Accidents Vasculaires Cerebraux. A Propos d'un Essai Comparatif de Traitment Preventif [these pour le Doctorat d'Etat en Medicine]. Toulouse (France): Universite Paul Sabatier, 1981. ">Pince 1981</a>; <a href="./references#CD000029-bbs2-0009" title="TurpieAG , DobkinB , McKennaR . A trial of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 1983.001.6.188)1983. ">Turpie 1983</a>); these trials did not formally evaluate survival free of dependency for activities of daily living. Progression of stroke symptoms measured by the Scandinavian Stroke Supervision Scale was the primary outcome event of <a href="./references#CD000029-bbs2-0008" title="Rödén-Jüllig Å, BrittonM , MalmkvistK , LeijdB . Aspirin in the prevention of progressing stroke: a randomized controlled study. Journal of Internal Medicine2003;254:584-90. ">Rödén‐Jüllig 2003</a>. Recurrence of stroke or speed of infarct progression was the primary outcome of <a href="./references#CD000029-bbs2-0011" title="ZhaoY , YangW , TanZ , WangW , XiaoW , ZengJ , et al. Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial. Stroke and Vascular Neurology2017;2:e000072. ">Zhao 2017</a>. Further additional outcomes included death from all causes at end of follow‐up, PE, symptomatic ICH, major extracranial haemorrhage, or complete recovery from stroke (see <a href="./full#CD000029-tbl-0001">summary of findings Table 1</a>). No trials systematically assessed quality of life. </p> </section> </section> <section id="CD000029-sec-0050"> <h4 class="title">Excluded studies</h4> <p>We excluded five trials for a variety of reasons (see <a href="./references#CD000029-sec-0123" title="">Characteristics of excluded studies</a> table). </p> </section> <section id="CD000029-sec-0051"> <h4 class="title">Studies awaiting classification</h4> <p>There are no studies awaiting classification.</p> </section> <section id="CD000029-sec-0052"> <h4 class="title">Ongoing studies</h4> <p>We found no ongoing studies.</p> </section> </section> <section id="CD000029-sec-0053"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD000029-sec-0054"> <h4 class="title">Baseline characteristics</h4> <p>Risk of bias of all 11 studies is summarised in <a href="#CD000029-fig-0002">Figure 2</a> and <a href="#CD000029-fig-0003">Figure 3</a>. <a href="./references#CD000029-bbs2-0009" title="TurpieAG , DobkinB , McKennaR . A trial of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 1983.001.6.188)1983. ">Turpie 1983</a> could not be accessed, and adequate assessment of risk of bias using the RoB1 tool could not be performed, therefore unclear risk of bias is reported for each category. The large numbers of participants randomised in <a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a> and <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a> resulted in an equal distribution of baseline participant characteristics between the treatment and control groups. In two smaller trials (<a href="./references#CD000029-bbs2-0006" title="Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet1995;346:1509-14. ">MAST‐I 1995</a>; <a href="./references#CD000029-bbs2-0010" title="UtsumiH . Evaluation of utility of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 001.6.128)1984. ">Utsumi 1988</a>), there were significant imbalances between the treatment and control groups in potentially important baseline factors (level of consciousness in <a href="./references#CD000029-bbs2-0010" title="UtsumiH . Evaluation of utility of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 001.6.128)1984. ">Utsumi 1988</a>, and time to treatment in <a href="./references#CD000029-bbs2-0006" title="Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet1995;346:1509-14. ">MAST‐I 1995</a>), but these differences cannot bias the overall results due to the small numbers of participants involved. </p> <div class="figure" id="CD000029-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD000029-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD000029-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000029-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> <section id="CD000029-sec-0055"> <h4 class="title">Random sequence generation</h4> <p>Eight trials had low risk of bias for this category because they explicitly stated an appropriate method of random sequence generation (<a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>; <a href="./references#CD000029-bbs2-0003" title="Di CesareF , MancusoJ , WoodwardP , BednarMM , LoudonPT . Phosphodiesterase-5 inhibitor PF-03049423 effect on stroke recovery: a double-blind, placebo-controlled randomized clinical trial. Journal of Stroke and Cerebrovascular Diseases2016;25:642-9. ">Di Cesare 2016</a>; <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>; <a href="./references#CD000029-bbs2-0005" title="KhatriP , KleindorferDO , DevlinT , SawyerRN , StarrM , MejillaJ , et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits. JAMA2018;320:156-66. ">Khatri 2018</a>; <a href="./references#CD000029-bbs2-0006" title="Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet1995;346:1509-14. ">MAST‐I 1995</a>; <a href="./references#CD000029-bbs2-0008" title="Rödén-Jüllig Å, BrittonM , MalmkvistK , LeijdB . Aspirin in the prevention of progressing stroke: a randomized controlled study. Journal of Internal Medicine2003;254:584-90. ">Rödén‐Jüllig 2003</a>; <a href="./references#CD000029-bbs2-0010" title="UtsumiH . Evaluation of utility of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 001.6.128)1984. ">Utsumi 1988</a>; <a href="./references#CD000029-bbs2-0011" title="ZhaoY , YangW , TanZ , WangW , XiaoW , ZengJ , et al. Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial. Stroke and Vascular Neurology2017;2:e000072. ">Zhao 2017</a>). <a href="./references#CD000029-bbs2-0002" title="CiuffettiG , AisaG , MercuriM , LombardiniR , PaltricciaR , NeriC , et al. Effects of ticlopidine on the neurologic outcome and the hemorheologic pattern in the postacute phase of ischemic stroke: a pilot study. Angiology1990;41:505-11. ">Ciuffetti 1990</a> had high risk of bias because groups were divided based upon age, sex, and score on Hachinski's Scale, and, therefore, the participants were not randomised. <a href="./references#CD000029-bbs2-0007" title="PinceJ . Thromboses Veineuses des Membres Inferieures et Embolies Pulmonaires au Cours des Accidents Vasculaires Cerebraux. A Propos d'un Essai Comparatif de Traitment Preventif [these pour le Doctorat d'Etat en Medicine]. Toulouse (France): Universite Paul Sabatier, 1981. ">Pince 1981</a> was deemed unclear risk of bias as a method of random sequence generation was not directly reported. <a href="./references#CD000029-bbs2-0009" title="TurpieAG , DobkinB , McKennaR . A trial of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 1983.001.6.188)1983. ">Turpie 1983</a> could not be accessed. </p> </section> <section id="CD000029-sec-0056"> <h4 class="title">Allocation concealment</h4> <p>Seven trials had low risk of bias for allocation concealment because they described the method used to conceal the allocation sequence in sufficient detail (<a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>; <a href="./references#CD000029-bbs2-0003" title="Di CesareF , MancusoJ , WoodwardP , BednarMM , LoudonPT . Phosphodiesterase-5 inhibitor PF-03049423 effect on stroke recovery: a double-blind, placebo-controlled randomized clinical trial. Journal of Stroke and Cerebrovascular Diseases2016;25:642-9. ">Di Cesare 2016</a>; <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>; <a href="./references#CD000029-bbs2-0006" title="Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet1995;346:1509-14. ">MAST‐I 1995</a>; <a href="./references#CD000029-bbs2-0008" title="Rödén-Jüllig Å, BrittonM , MalmkvistK , LeijdB . Aspirin in the prevention of progressing stroke: a randomized controlled study. Journal of Internal Medicine2003;254:584-90. ">Rödén‐Jüllig 2003</a>; <a href="./references#CD000029-bbs2-0010" title="UtsumiH . Evaluation of utility of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 001.6.128)1984. ">Utsumi 1988</a>; <a href="./references#CD000029-bbs2-0011" title="ZhaoY , YangW , TanZ , WangW , XiaoW , ZengJ , et al. Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial. Stroke and Vascular Neurology2017;2:e000072. ">Zhao 2017</a>). One trial was at high risk of bias because it was not a randomised study, and so there was no allocation concealment (<a href="./references#CD000029-bbs2-0002" title="CiuffettiG , AisaG , MercuriM , LombardiniR , PaltricciaR , NeriC , et al. Effects of ticlopidine on the neurologic outcome and the hemorheologic pattern in the postacute phase of ischemic stroke: a pilot study. Angiology1990;41:505-11. ">Ciuffetti 1990</a>). Two studies were at unclear risk of bias as there was no statement regarding allocation concealment (<a href="./references#CD000029-bbs2-0005" title="KhatriP , KleindorferDO , DevlinT , SawyerRN , StarrM , MejillaJ , et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits. JAMA2018;320:156-66. ">Khatri 2018</a>; <a href="./references#CD000029-bbs2-0007" title="PinceJ . Thromboses Veineuses des Membres Inferieures et Embolies Pulmonaires au Cours des Accidents Vasculaires Cerebraux. A Propos d'un Essai Comparatif de Traitment Preventif [these pour le Doctorat d'Etat en Medicine]. Toulouse (France): Universite Paul Sabatier, 1981. ">Pince 1981</a>). <a href="./references#CD000029-bbs2-0009" title="TurpieAG , DobkinB , McKennaR . A trial of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 1983.001.6.188)1983. ">Turpie 1983</a> could not be accessed. </p> </section> <section id="CD000029-sec-0057"> <h4 class="title">Blinding of participants and personnel</h4> <p>Four studies had low risk of bias as it was clearly stated that participants and personnel were blinded from knowledge of which intervention a participant received and details of how this was done (<a href="./references#CD000029-bbs2-0003" title="Di CesareF , MancusoJ , WoodwardP , BednarMM , LoudonPT . Phosphodiesterase-5 inhibitor PF-03049423 effect on stroke recovery: a double-blind, placebo-controlled randomized clinical trial. Journal of Stroke and Cerebrovascular Diseases2016;25:642-9. ">Di Cesare 2016</a>; <a href="./references#CD000029-bbs2-0005" title="KhatriP , KleindorferDO , DevlinT , SawyerRN , StarrM , MejillaJ , et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits. JAMA2018;320:156-66. ">Khatri 2018</a>; <a href="./references#CD000029-bbs2-0007" title="PinceJ . Thromboses Veineuses des Membres Inferieures et Embolies Pulmonaires au Cours des Accidents Vasculaires Cerebraux. A Propos d'un Essai Comparatif de Traitment Preventif [these pour le Doctorat d'Etat en Medicine]. Toulouse (France): Universite Paul Sabatier, 1981. ">Pince 1981</a>; <a href="./references#CD000029-bbs2-0008" title="Rödén-Jüllig Å, BrittonM , MalmkvistK , LeijdB . Aspirin in the prevention of progressing stroke: a randomized controlled study. Journal of Internal Medicine2003;254:584-90. ">Rödén‐Jüllig 2003</a>). Seven studies had unclear risk of bias because there was insufficient evidence to judge whether participants and personnel were truly blinded (<a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>; <a href="./references#CD000029-bbs2-0002" title="CiuffettiG , AisaG , MercuriM , LombardiniR , PaltricciaR , NeriC , et al. Effects of ticlopidine on the neurologic outcome and the hemorheologic pattern in the postacute phase of ischemic stroke: a pilot study. Angiology1990;41:505-11. ">Ciuffetti 1990</a>; <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>; <a href="./references#CD000029-bbs2-0005" title="KhatriP , KleindorferDO , DevlinT , SawyerRN , StarrM , MejillaJ , et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits. JAMA2018;320:156-66. ">Khatri 2018</a>; <a href="./references#CD000029-bbs2-0006" title="Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet1995;346:1509-14. ">MAST‐I 1995</a>; <a href="./references#CD000029-bbs2-0010" title="UtsumiH . Evaluation of utility of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 001.6.128)1984. ">Utsumi 1988</a>; <a href="./references#CD000029-bbs2-0011" title="ZhaoY , YangW , TanZ , WangW , XiaoW , ZengJ , et al. Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial. Stroke and Vascular Neurology2017;2:e000072. ">Zhao 2017</a>). Three of these studies reported that they were double‐blind (<a href="./references#CD000029-bbs2-0002" title="CiuffettiG , AisaG , MercuriM , LombardiniR , PaltricciaR , NeriC , et al. Effects of ticlopidine on the neurologic outcome and the hemorheologic pattern in the postacute phase of ischemic stroke: a pilot study. Angiology1990;41:505-11. ">Ciuffetti 1990</a>; <a href="./references#CD000029-bbs2-0010" title="UtsumiH . Evaluation of utility of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 001.6.128)1984. ">Utsumi 1988</a>; <a href="./references#CD000029-bbs2-0011" title="ZhaoY , YangW , TanZ , WangW , XiaoW , ZengJ , et al. Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial. Stroke and Vascular Neurology2017;2:e000072. ">Zhao 2017</a>). However, it was not reported how blinding was done, or whether participants were definitely blinded. <a href="./references#CD000029-bbs2-0009" title="TurpieAG , DobkinB , McKennaR . A trial of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 1983.001.6.188)1983. ">Turpie 1983</a> could not be accessed. </p> </section> <section id="CD000029-sec-0058"> <h4 class="title">Blinding of outcome assessment</h4> <p>Three studies had low risk of bias as they clearly described the measures used to blind outcome assessors from knowledge of which intervention a participant received (<a href="./references#CD000029-bbs2-0003" title="Di CesareF , MancusoJ , WoodwardP , BednarMM , LoudonPT . Phosphodiesterase-5 inhibitor PF-03049423 effect on stroke recovery: a double-blind, placebo-controlled randomized clinical trial. Journal of Stroke and Cerebrovascular Diseases2016;25:642-9. ">Di Cesare 2016</a>; <a href="./references#CD000029-bbs2-0006" title="Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet1995;346:1509-14. ">MAST‐I 1995</a>; <a href="./references#CD000029-bbs2-0008" title="Rödén-Jüllig Å, BrittonM , MalmkvistK , LeijdB . Aspirin in the prevention of progressing stroke: a randomized controlled study. Journal of Internal Medicine2003;254:584-90. ">Rödén‐Jüllig 2003</a>). Seven studies had unclear risk of bias because there was insufficient evidence to judge whether outcome assessors were blinded or not. <a href="./references#CD000029-bbs2-0009" title="TurpieAG , DobkinB , McKennaR . A trial of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 1983.001.6.188)1983. ">Turpie 1983</a> could not be accessed. </p> </section> <section id="CD000029-sec-0059"> <h4 class="title">Incomplete outcome data</h4> <p>Ten trials had low risk of bias for incomplete outcome data (<a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>; <a href="./references#CD000029-bbs2-0002" title="CiuffettiG , AisaG , MercuriM , LombardiniR , PaltricciaR , NeriC , et al. Effects of ticlopidine on the neurologic outcome and the hemorheologic pattern in the postacute phase of ischemic stroke: a pilot study. Angiology1990;41:505-11. ">Ciuffetti 1990</a>; <a href="./references#CD000029-bbs2-0003" title="Di CesareF , MancusoJ , WoodwardP , BednarMM , LoudonPT . Phosphodiesterase-5 inhibitor PF-03049423 effect on stroke recovery: a double-blind, placebo-controlled randomized clinical trial. Journal of Stroke and Cerebrovascular Diseases2016;25:642-9. ">Di Cesare 2016</a>; <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>; <a href="./references#CD000029-bbs2-0005" title="KhatriP , KleindorferDO , DevlinT , SawyerRN , StarrM , MejillaJ , et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits. JAMA2018;320:156-66. ">Khatri 2018</a>; <a href="./references#CD000029-bbs2-0006" title="Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet1995;346:1509-14. ">MAST‐I 1995</a>; <a href="./references#CD000029-bbs2-0007" title="PinceJ . Thromboses Veineuses des Membres Inferieures et Embolies Pulmonaires au Cours des Accidents Vasculaires Cerebraux. A Propos d'un Essai Comparatif de Traitment Preventif [these pour le Doctorat d'Etat en Medicine]. Toulouse (France): Universite Paul Sabatier, 1981. ">Pince 1981</a>; <a href="./references#CD000029-bbs2-0008" title="Rödén-Jüllig Å, BrittonM , MalmkvistK , LeijdB . Aspirin in the prevention of progressing stroke: a randomized controlled study. Journal of Internal Medicine2003;254:584-90. ">Rödén‐Jüllig 2003</a>; <a href="./references#CD000029-bbs2-0010" title="UtsumiH . Evaluation of utility of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 001.6.128)1984. ">Utsumi 1988</a>; <a href="./references#CD000029-bbs2-0011" title="ZhaoY , YangW , TanZ , WangW , XiaoW , ZengJ , et al. Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial. Stroke and Vascular Neurology2017;2:e000072. ">Zhao 2017</a>). <a href="./references#CD000029-bbs2-0005" title="KhatriP , KleindorferDO , DevlinT , SawyerRN , StarrM , MejillaJ , et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits. JAMA2018;320:156-66. ">Khatri 2018</a> was at low risk of bias as, although the trial lost 22% of participants to follow‐up, the missing data were imputed via a hot‐deck method to account for missing outcome data. <a href="./references#CD000029-bbs2-0009" title="TurpieAG , DobkinB , McKennaR . A trial of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 1983.001.6.188)1983. ">Turpie 1983</a> could not be accessed. </p> </section> <section id="CD000029-sec-0060"> <h4 class="title">Selective reporting</h4> <p>Eight studies had low risk of bias for bias in selection of reported results (<a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>; <a href="./references#CD000029-bbs2-0002" title="CiuffettiG , AisaG , MercuriM , LombardiniR , PaltricciaR , NeriC , et al. Effects of ticlopidine on the neurologic outcome and the hemorheologic pattern in the postacute phase of ischemic stroke: a pilot study. Angiology1990;41:505-11. ">Ciuffetti 1990</a>; <a href="./references#CD000029-bbs2-0003" title="Di CesareF , MancusoJ , WoodwardP , BednarMM , LoudonPT . Phosphodiesterase-5 inhibitor PF-03049423 effect on stroke recovery: a double-blind, placebo-controlled randomized clinical trial. Journal of Stroke and Cerebrovascular Diseases2016;25:642-9. ">Di Cesare 2016</a>; <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>; <a href="./references#CD000029-bbs2-0005" title="KhatriP , KleindorferDO , DevlinT , SawyerRN , StarrM , MejillaJ , et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits. JAMA2018;320:156-66. ">Khatri 2018</a>; <a href="./references#CD000029-bbs2-0006" title="Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet1995;346:1509-14. ">MAST‐I 1995</a>; <a href="./references#CD000029-bbs2-0008" title="Rödén-Jüllig Å, BrittonM , MalmkvistK , LeijdB . Aspirin in the prevention of progressing stroke: a randomized controlled study. Journal of Internal Medicine2003;254:584-90. ">Rödén‐Jüllig 2003</a>; <a href="./references#CD000029-bbs2-0011" title="ZhaoY , YangW , TanZ , WangW , XiaoW , ZengJ , et al. Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial. Stroke and Vascular Neurology2017;2:e000072. ">Zhao 2017</a>). Two studies had unclear risk of bias in selection of reported results because a prespecified analysis plan was not clearly reported (<a href="./references#CD000029-bbs2-0007" title="PinceJ . Thromboses Veineuses des Membres Inferieures et Embolies Pulmonaires au Cours des Accidents Vasculaires Cerebraux. A Propos d'un Essai Comparatif de Traitment Preventif [these pour le Doctorat d'Etat en Medicine]. Toulouse (France): Universite Paul Sabatier, 1981. ">Pince 1981</a>; <a href="./references#CD000029-bbs2-0010" title="UtsumiH . Evaluation of utility of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 001.6.128)1984. ">Utsumi 1988</a>). Funnel plots did not suggest substantial publication bias in respect of the primary outcome (<a href="#CD000029-fig-0004">Figure 4</a>), or death at the scheduled end of follow‐up (<a href="#CD000029-fig-0005">Figure 5</a>). <a href="./references#CD000029-bbs2-0009" title="TurpieAG , DobkinB , McKennaR . A trial of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 1983.001.6.188)1983. ">Turpie 1983</a> could not be accessed. </p> <div class="figure" id="CD000029-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Antiplatelet agent versus control in acute presumed ischaemic stroke, outcome: 1.1 Death or dependence at end of follow‐up." data-id="CD000029-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antiplatelet agent versus control in acute presumed ischaemic stroke, outcome: 1.1 Death or dependence at end of follow‐up. </p> </div> </div> </div> <div class="figure" id="CD000029-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Antiplatelet agent versus control in acute presumed ischaemic stroke, outcome: 1.2 Deaths from all causes during treatment period." data-id="CD000029-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antiplatelet agent versus control in acute presumed ischaemic stroke, outcome: 1.2 Deaths from all causes during treatment period. </p> </div> </div> </div> </section> <section id="CD000029-sec-0061"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD000029-bbs2-0009" title="TurpieAG , DobkinB , McKennaR . A trial of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 1983.001.6.188)1983. ">Turpie 1983</a> could not be accessed, and, therefore, adequate assessment of risk of bias using the RoB 1 tool could not be done (<a href="#CD000029-fig-0002">Figure 2</a>; <a href="#CD000029-fig-0003">Figure 3</a>). <a href="./references#CD000029-bbs2-0007" title="PinceJ . Thromboses Veineuses des Membres Inferieures et Embolies Pulmonaires au Cours des Accidents Vasculaires Cerebraux. A Propos d'un Essai Comparatif de Traitment Preventif [these pour le Doctorat d'Etat en Medicine]. Toulouse (France): Universite Paul Sabatier, 1981. ">Pince 1981</a> was a thesis published in French and other potential sources of bias could not be fully excluded based on the information available. </p> </section> </section> <section id="CD000029-sec-0062"> <h3 class="title" id="CD000029-sec-0062">Effects of interventions</h3> <p>See: <a href="./full#CD000029-tbl-0001"><b>Summary of findings 1</b> Antiplatelet drug compared to control in acute presumed ischaemic stroke for acute ischaemic stroke</a> </p> <section id="CD000029-sec-0063"> <h4 class="title">Outcome 1.1 (primary outcome): death or dependence at end of follow‐up</h4> <p>For the primary outcome, antiplatelet therapy was associated with a significant reduction in the odds of death or being dependent at final follow‐up (OR 0.95, 95% CI 0.91 to 0.99; P = 0.008 7 RCTs, 42,034 participants; moderate‐certainty evidence; <a href="./references#CD000029-fig-0006" title="">Analysis 1.1</a>). For aspirin, for every 1000 people treated, 13 people would avoid death or dependency (NNTB 79; <a href="#CD000029-tbl-0002">Table 1</a>). A prespecified sensitivity analysis (data not shown in forest plots) showed no difference in the effect of treatment on death or dependence at final follow‐up between trials that were double‐blind (OR 0.95, 95% CI 0.90 to 1.01) or not (OR 0.94, 95% CI 0.89 to 1.00). A post‐hoc subgroup analysis (data not shown in forest plots) restricted to the subset of participants in whom the initial stroke was due to intracerebral haemorrhage and who had been inadvertently randomised in the trials (597 in <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a> and 174 in <a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>) showed that the odds of a poor outcome were lower among those allocated to aspirin (OR 0.68, 95% CI 0.49 to 0.94), although the CIs were wide (<a href="./references#CD000029-bbs2-0046" title="KeirS , WardlawJ , SandercockPA , ChenZ . Antithrombotic therapy in patients with any form of intracranial haemorrhage: a systematic review of the available controlled studies. Cerebrovascular Diseases2002;14(3-4):197-206.">Keir 2002</a>). In <a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>, 11 participants in the aspirin group and five participants in the control group were not accounted for in this analysis. Assuming a worst‐case scenario (i.e. where all participants in the experimental group were assumed to be either dead or dependent, and all participants in the control group recovered fully), the result was no longer statistically significant (OR 0.74, 95% CI 0.53 to 1.03). Thus, these data do not provide clear evidence of any harm to people with haemorrhagic stroke inadvertently treated with aspirin. </p> <div class="table" id="CD000029-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Absolute risk reductions of aspirin treatment in acute stroke</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control event rate<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of events avoided<sup>b</sup> </b> </p> <p><b>(per 1000 people treated (95% CI))</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>NNTB or NNTH<sup>b</sup> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death or dependence at end of follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (3 to 23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTB 79 (43 to 400)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deaths from all causes during follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (2 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTB 108 (66 to 436)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary embolism during treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0 to 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTB 693 (427 to 6700)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent ischaemic/unknown stroke during treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (4 to 10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTB 140 (104 to 248)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symptomatic intracranial haemorrhage during treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2 (i.e. 2 extra) (−4 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTH 574 (254 to 126,010)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any recurrent stroke/intracranial haemorrhage during treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (1 to 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTB 200 (123 to 868)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major extracranial haemorrhage during treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4 (i.e. 4 extra) (−7 to −2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTH 245 (153 to 481)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Complete recovery from stroke (post hoc)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (2 to 21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTB 89 (49 to 523)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; NNTB: number needed to treat for an additional beneficial outcome; NNTH: number needed to treat for an additional harmful outcome. </p> <p><sup>a</sup>Estimated from the mean of the control event rate in the two largest trials (<a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>; <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>).<br/><sup>b</sup>Estimated by applying the Peto odds ratio for the outcome for studies of aspirin. Calculator is available at: <a href="https://www.dcn.ed.ac.uk/csrg/entity/entity_NNT2.asp" target="_blank">www.dcn.ed.ac.uk/csrg/entity/entity_NNT2.asp</a>. </p> </div> </div> </section> <section id="CD000029-sec-0064"> <h4 class="title">Outcome 1.2: deaths from any cause during treatment period</h4> <p>Antiplatelet therapy was associated with a nominally significant reduction in death at the end of the treatment period (OR 0.92, 95% CI 0.85 to 1.00; P = 0.05; 8 studies, 41,483 participants; very low‐certainty evidence; <a href="./references#CD000029-fig-0007" title="">Analysis 1.2</a>). </p> </section> <section id="CD000029-sec-0065"> <h4 class="title">Outcome 1.3: deaths from any cause during follow‐up</h4> <p>Antiplatelet therapy was associated with a reduction in the odds of death at a final follow‐up of greater than one month (OR 0.93, 95% CI 0.87 to 0.98; P = 0.01; 10 studies, 41,929 participants; very low‐certainty evidence; <a href="./references#CD000029-fig-0008" title="">Analysis 1.3</a>). For aspirin, for every 1000 people treated nine people would avoid death (NNTB 108; <a href="#CD000029-tbl-0002">Table 1</a>). A prespecified sensitivity analysis showed no difference in the effect of treatment on death at final follow‐up between trials which were of a double‐blind design (OR 0.87, 95% CI 0.76 to 1.00) or not (OR 0.94, 95% CI 0.87 to 1.00). </p> </section> <section id="CD000029-sec-0066"> <h4 class="title">Outcome 1.4: deep vein thrombosis during treatment period</h4> <p>Two trials that included randomised data from 133 participants (less than 0.3% of participants included in the overall review) sought to systematically determine the effect of antiplatelet agents on the occurrence of symptomatic or asymptomatic DVT at the end of the treatment period, as detected by I<sup>125</sup> fibrinogen scanning (<a href="./references#CD000029-bbs2-0007" title="PinceJ . Thromboses Veineuses des Membres Inferieures et Embolies Pulmonaires au Cours des Accidents Vasculaires Cerebraux. A Propos d'un Essai Comparatif de Traitment Preventif [these pour le Doctorat d'Etat en Medicine]. Toulouse (France): Universite Paul Sabatier, 1981. ">Pince 1981</a>; <a href="./references#CD000029-bbs2-0009" title="TurpieAG , DobkinB , McKennaR . A trial of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 1983.001.6.188)1983. ">Turpie 1983</a>). DVT occurred in 16/67 (23.9%) of participants allocated to antiplatelet treatment and 19/66 (28.8%) of participants allocated to control (OR 0.78, 95% CI 0.36 to 1.67; P = 0.52; 2 RCTs, 133 participants; very low‐certainty evidence; <a href="./references#CD000029-fig-0009" title="">Analysis 1.4</a>). There was substantial heterogeneity between these two trials (I<sup>2</sup> = 82.9%), one of which involved ticlopidine and one a combination of aspirin and dipyridamole. This heterogeneity may have been due to chance or to the fact that the time between stroke onset and starting treatment varied in the two trials: less than six days in <a href="./references#CD000029-bbs2-0007" title="PinceJ . Thromboses Veineuses des Membres Inferieures et Embolies Pulmonaires au Cours des Accidents Vasculaires Cerebraux. A Propos d'un Essai Comparatif de Traitment Preventif [these pour le Doctorat d'Etat en Medicine]. Toulouse (France): Universite Paul Sabatier, 1981. ">Pince 1981</a>, and less than four weeks in <a href="./references#CD000029-bbs2-0009" title="TurpieAG , DobkinB , McKennaR . A trial of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 1983.001.6.188)1983. ">Turpie 1983</a>. Sensitivity analyses were not possible for this outcome due to the limited amount of data. </p> </section> <section id="CD000029-sec-0067"> <h4 class="title">Outcome 1.5: pulmonary embolism during treatment period</h4> <p>No trial systematically sought asymptomatic PE by performing ventilation‐perfusion scans or using CTPA in all participants at the end of treatment. Antiplatelet therapy was associated with a reduction in the odds of PE (OR 0.71, 95% CI 0.53 to 0.96; P = 0.03; 7 RCTs, 41,042 participants; very low‐certainty evidence; <a href="./references#CD000029-fig-0010" title="">Analysis 1.5</a>). For aspirin, for every 1000 people treated, one person would avoid PE (NNTB 693; <a href="#CD000029-tbl-0002">Table 1</a>). This may be an underestimate if antiplatelet treatment prevented both major and minor PE since no trial systematically sought minor PE. </p> </section> <section id="CD000029-sec-0068"> <h4 class="title">Outcome 1.6: recurrent ischaemic or unknown stroke during treatment period</h4> <p>Data on recurrent stroke were available from nine trials, which systematically sought to record early recurrent strokes that were definitely ischaemic (CT scan excluded haemorrhage) or probably ischaemic, that is in which the cerebral pathology was unknown because brain imaging had not been performed. A total of 495/526 reported recurrent ischaemic strokes occurred in <a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a> and <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>. The use of antiplatelet agents (chiefly aspirin) was associated with a reduction in recurrent ischaemic strokes (OR 0.79, 95% CI 0.70 to 0.88; P &lt; 0.00001; 9 RCTs, 41,625 participants; very low‐certainty evidence; <a href="./references#CD000029-fig-0011" title="">Analysis 1.6</a>). For every 1000 people treated with aspirin, seven people would avoid recurrent ischaemic stroke (NNTB 140; <a href="#CD000029-tbl-0002">Table 1</a>). </p> </section> <section id="CD000029-sec-0069"> <h4 class="title">Outcome 1.7: symptomatic intracranial haemorrhage during treatment period</h4> <p>There were data for nine trials. It was unclear (even after correspondence) how three small trials detected haemorrhages (<a href="./references#CD000029-bbs2-0007" title="PinceJ . Thromboses Veineuses des Membres Inferieures et Embolies Pulmonaires au Cours des Accidents Vasculaires Cerebraux. A Propos d'un Essai Comparatif de Traitment Preventif [these pour le Doctorat d'Etat en Medicine]. Toulouse (France): Universite Paul Sabatier, 1981. ">Pince 1981</a>; <a href="./references#CD000029-bbs2-0009" title="TurpieAG , DobkinB , McKennaR . A trial of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 1983.001.6.188)1983. ">Turpie 1983</a>; <a href="./references#CD000029-bbs2-0010" title="UtsumiH . Evaluation of utility of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 001.6.128)1984. ">Utsumi 1988</a>). However, it was likely that participants who deteriorated neurologically were scanned using CT, or that haemorrhages were found at autopsy. In one trial, four participants, two in each group, were excluded after randomisation because they had intracerebral haemorrhage (<a href="./references#CD000029-bbs2-0007" title="PinceJ . Thromboses Veineuses des Membres Inferieures et Embolies Pulmonaires au Cours des Accidents Vasculaires Cerebraux. A Propos d'un Essai Comparatif de Traitment Preventif [these pour le Doctorat d'Etat en Medicine]. Toulouse (France): Universite Paul Sabatier, 1981. ">Pince 1981</a>). These participants were included as having symptomatic ICH in this analysis. In the trials where participants did not have a CT scan before randomisation, it was difficult to determine whether any ICH first identified after treatment had been started was new or had been present before randomisation. For the purposes of this analysis, we assumed that all such haemorrhages were new. Antiplatelet therapy increased the odds of symptomatic ICH, but this was not statistically significant (OR 1.18, 95% CI 0.97 to 1.44; P = 0.10; 9 RCTs, 41,652 participants; very low‐certainty evidence; <a href="./references#CD000029-fig-0012" title="">Analysis 1.7</a>). For every 1000 people treated with aspirin, two people would have a symptomatic ICH; the number needed to treat to harm (NNTH) was 574 (<a href="#CD000029-tbl-0002">Table 1</a>). There was the possibility of some bias within these data as there may have been a lower threshold for rescanning participants who had deteriorated clinically if they were known to be receiving antithrombotic treatment (e.g. in <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>, which was not blinded). </p> </section> <section id="CD000029-sec-0070"> <h4 class="title">Outcome 1.8: recurrent stroke or intracranial haemorrhage during treatment period</h4> <p>Immediate use of antiplatelet agents reduced the odds of ischaemic stroke but also appeared to increase the odds of symptomatic ICH. An outcome which combines these two (without double counting, that is participant allowed only one of ischaemic stroke or ICH with the first event being the one which was included) was useful for assessing the net short‐term effects of antiplatelet agents. However, symptomatic ICHs are more likely to cause death or disability than ischaemic recurrences, and so the severity of the recurrence also needed to be considered. No trial reported the severity of recurrences. </p> <p>Antiplatelet therapy was associated with a net reduction in the odds of any recurrent stroke/ICH (OR 0.88, 95% CI 0.79 to 0.97; P = 0.01; 7 RCTs, 41,042 participants; very low‐certainty evidence; <a href="./references#CD000029-fig-0013" title="">Analysis 1.8</a>). For every 1000 people treated with aspirin, five people would avoid recurrent ischaemic stroke or symptomatic ICH (NNTB 200; <a href="#CD000029-tbl-0002">Table 1</a>). </p> </section> <section id="CD000029-sec-0071"> <h4 class="title">Outcome 1.9: major extracranial haemorrhage during treatment period</h4> <p>Allocation to antiplatelet agents was associated with a significant increase in major extracranial haemorrhage (OR 1.69, 95% CI 1.35 to 2.11; P &lt; 0.00001; 7 RCTs, 41,042 participants; very low‐certainty evidence; <a href="./references#CD000029-fig-0014" title="">Analysis 1.9</a>). For every 1000 people treated with aspirin, four people would have a symptomatic extracranial haemorrhage (NNTH 245; <a href="#CD000029-tbl-0002">Table 1</a>). </p> </section> <section id="CD000029-sec-0072"> <h4 class="title">Outcome 1.10: complete recovery from stroke (post hoc)</h4> <p>Two trials including randomised data on 40,541 participants (98% of participants included in the overall review) reported complete recovery from stroke (<a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>; <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>). Allocation to antiplatelet therapy increased the odds of a complete recovery (OR 1.06, 95% CI 1.01 to 1.11; P = 0.01; 2 RCTs, 40,541 participants; moderate‐certainty evidence; <a href="./references#CD000029-fig-0015" title="">Analysis 1.10</a>). For every 1000 people treated with aspirin, an extra 11 people would make a complete recovery (NNTB 89; <a href="#CD000029-tbl-0002">Table 1</a>). </p> </section> <section id="CD000029-sec-0073"> <h4 class="title">Re‐evaluation of the planned sensitivity and subgroup analyses in light of the available data </h4> <p>After an evaluation of the available evidence from the randomised trials, it became apparent that three of the planned subgroup sensitivity analyses were inappropriate. These were the analyses restricted to trials: in which participants were randomised within 48 hours of the stroke; with adequate concealment of randomisation; and with 100% CT scans prior to randomisation. As most data came from trials that randomised participants within 48 hours of stroke onset, the planned subgroup sensitivity analysis evaluating the effects of treatment beyond 48 hours was largely uninformative. Similarly, the analyses based on the concealment of treatment allocation were uninformative about trials with inadequate concealment as these trials contributed so few data. An analysis based on whether or not all participants had brain imaging prior to randomisation to rule out haemorrhage would exclude <a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a> and <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>, and would, therefore, disregard 98% of the data. An individual participant data analysis has examined the effect subdivided by whether participants had CT prior to randomisation or not; there was no clear heterogeneity of effect (<a href="./references#CD000029-bbs2-0030" title="ChenZM , SandercockP , PanHC , CounsellC , CollinsR , LiuLS , et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40,000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. On behalf of the CAST and IST Collaborative Groups. Stroke2000;31:1240-9.">Chen 2000</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000029-sec-0074" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000029-sec-0074"></div> <section id="CD000029-sec-0075"> <h3 class="title" id="CD000029-sec-0075">Strength of evidence of benefit on major outcomes</h3> <p>This systematic review once again reliably emphasised that antiplatelet therapy is safe and effective in the acute phase of ischaemic stroke. The conclusion is based on data from over 40,000 participants. Ninety‐six per cent of the data came from two trials of medium‐dose aspirin, that is 160 mg to 300 mg daily (<a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>; <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>). Overall, antiplatelet therapy with aspirin started within 48 hours of onset of presumed ischaemic stroke was beneficial. Although associated with a small but definite risk of bleeding, this hazard was offset by the reduction in recurrent ischaemic stroke. The analysis of the effects of aspirin among participants who were first scanned after randomisation and who turned out to have had a haemorrhagic stroke was reassuring. </p> <p>The benefits of a short course of antiplatelet therapy in acute ischaemic stroke compare very favourably with longer‐term antiplatelet therapy for secondary prevention in vascular disease. Two to four weeks of treatment in <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a> and <a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a> resulted in about eight fewer deaths per 1000 participants treated, whereas, in long‐term secondary prevention, one month of antiplatelet therapy typically avoids fewer than one death per 1000 (<a href="./references#CD000029-bbs2-0021" title="Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ2002;324:71-86.">ATC 2002</a>). Similarly, long‐term antiplatelet use prevents about one recurrent stroke per 1000 people per month (<a href="./references#CD000029-bbs2-0019" title="Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ1994;308:81-106.">ATC 1994a</a>; <a href="./references#CD000029-bbs2-0021" title="Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ2002;324:71-86.">ATC 2002</a>), whereas, in the acute phase of ischaemic stroke, one month of antiplatelet therapy prevents about four recurrent strokes per 1000 people (seven fewer ischaemic strokes and three extra haemorrhagic strokes). </p> <p>The main conclusions of this review have not changed from the last update, despite the exclusion of the trials of IV antiplatelet agents. Importantly, there now is no equipose in comparing antiplatelet therapy to placebo therapy given the worldwide acceptance of antiplatelet therapy as the standard of care. </p> </section> <section id="CD000029-sec-0076"> <h3 class="title" id="CD000029-sec-0076">Effects on venous thromboembolism</h3> <p>Aspirin reduced the odds of PE by 29%, but, since the reported rate of PE was low, the absolute benefit, one event prevented per 1000 participants treated, is very small. However, if there was a substantial under‐ascertainment of PE in the trials included in this systematic review, then the absolute benefits of aspirin may have been underestimated. Clinical series report a range of 0% to 3% for symptomatic PE (<a href="./references#CD000029-bbs2-0035" title="DavenportR , DennisM , WellwoodI , WarlowC . Complications after acute stroke. Stroke1996;27:415-20.">Davenport 1996</a>). If the observed 29% reduction in the odds of PE was applied to a population with a 3% risk of PE the absolute reduction would increase to eight for every 1000 people treated. It seems reasonable to conclude that routine use of aspirin alone in people with acute ischaemic stroke will reduce the risk of DVT and PE somewhat yet not be associated with any substantial excess of intracerebral haemorrhages. It remains unclear whether aspirin alone is as good as heparin alone at preventing venous thromboembolism in acute ischaemic stroke, but data from <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a> suggest no statistically or clinically significant difference between aspirin and heparin in the prevention of PE. </p> </section> <section id="CD000029-sec-0077"> <h3 class="title" id="CD000029-sec-0077">Robustness of the findings</h3> <p>The sensitivity analyses have shown that the conclusions about the benefits of antiplatelet therapy are robust. A meta‐analysis based on individual participant data from <a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a> and <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a> confirmed this (<a href="./references#CD000029-bbs2-0030" title="ChenZM , SandercockP , PanHC , CounsellC , CollinsR , LiuLS , et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40,000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. On behalf of the CAST and IST Collaborative Groups. Stroke2000;31:1240-9.">Chen 2000</a>). It showed no clear heterogeneity of treatment effect with delay in starting aspirin, age, gender, stroke type, infarct subtype, the presence of impaired consciousness or the presence or absence of atrial fibrillation. These results suggest that a wide variety of people with ischaemic stroke are likely to benefit from antiplatelet therapy with aspirin (<a href="./references#CD000029-bbs2-0030" title="ChenZM , SandercockP , PanHC , CounsellC , CollinsR , LiuLS , et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40,000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. On behalf of the CAST and IST Collaborative Groups. Stroke2000;31:1240-9.">Chen 2000</a>). As a result of the strength of evidence, aspirin is now recommended as a standard therapy. Four major evidence‐based guidelines make strong recommendations for the routine use of aspirin for all people with acute ischaemic stroke (<a href="./references#CD000029-bbs2-0033" title="Canadian Stroke Network and Heart and Stroke Foundation of Canada. Canadian best practice recommendations for stroke care: update 2010. www.canadianstrokenetwork.ca/ (accessed prior to 24 November 2021).">CSS 2010</a>; <a href="./references#CD000029-bbs2-0038" title="The European Stroke Organisation Executive Committee and the ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovascular Diseases2008;25::457-507. [DOI: 10.1159/000131083]">ESO 2008</a>; <a href="./references#CD000029-bbs2-0045" title="JauchEC , SaverJL , Adams HP Jr, BrunoA , ConnorsJJ , DemaerschalkBM , American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke2013;44:870-947. [DOI: 10.1161/STR.0b013e318284056a]">Jauch 2013</a>; <a href="./references#CD000029-bbs2-0056" title="Royal College of Physicians. National Clinical Guidelines for Stroke, Fifth Edition 2016. www.rcplondon.ac.uk/resources/stroke-guidelines (accessed prior to 24 November 2021).">RCP Guideline 2016</a>). </p> </section> <section id="CD000029-sec-0078"> <h3 class="title" id="CD000029-sec-0078">Public health impact</h3> <p>It can be argued that, although effective, the net benefits of aspirin are rather small when compared with the effects of stroke unit care (OR of death or dependency 0.79, 95% CI 0.68 to 0.90) (<a href="./references#CD000029-bbs2-0063" title="Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database of Systematic Reviews2013, Issue 9. Art. No: CD000197. [DOI: 10.1002/14651858.CD000197.pub3]">SUTC 2013</a>), and thrombolysis with tissue plasminogen activator within three hours of stroke (OR of death or dependency 0.71, 95% CI 0.52 to 0.96) (<a href="./references#CD000029-bbs2-0070" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews2009, Issue 4. Art. No: CD000213. [DOI: 10.1002/14651858.CD000213.pub2]">Wardlaw 2009</a>). However, aspirin is inexpensive, easy to administer, and safe, which increases its potential public health impact worldwide and especially in low‐ to middle‐income countries. In 2019, stroke ranked second in the leading causes of disability‐adjusted life years (DALYs) in the age groups 50 to 74 years and 75 years and older (<a href="./references#CD000029-bbs2-0039" title="GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet2020;396(10258):1204-22. [DOI: doi.org/10.1016/S0140-6736(20)30925-9]">GBD 2019</a>). In 2017, there were 11.9 million incident, 104.2 million prevalent, 6.2 million cases of stroke, and 132.1 million stroke‐related DALYs (<a href="./references#CD000029-bbs2-0047" title="KrishnamurthiRV , IkedaT , FeiginVL . Global, regional and country-specific burden of ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage: a systematic analysis of the Global Burden of Disease Study 2017. Neuroepidemiology2020;54:171-9. [DOI: doi.org/10.1159/000506396]">Krishnamurthi 2020</a>). The risk of death following stroke is highest in the immediate aftermath and treatment strategies should be aimed at lowering the risk of mortality during this period (<a href="./references#CD000029-bbs2-0049" title="MinhasJS , RobinsonTG . Latest developments in clinical stroke care. Journal of the Royal College of Physicians of Edinburgh2017;47(4):360-3. [DOI: 10.4997/JRCPE.2017.413]">Minhas 2017</a>). If treatment with aspirin prevents seven deaths per 1000, then an additional 36,400 lives could be saved worldwide per year with substantial numbers of survivors avoiding long‐term disability. </p> </section> <section id="CD000029-sec-0079"> <h3 class="title" id="CD000029-sec-0079">Aspirin dose and route of administration</h3> <p>The benefits of aspirin in acute stroke are drawn from trials that tested a dose of aspirin between 160 mg and 330 mg daily. In acute myocardial infarction, 160 mg is the lowest dose that has been shown to be effective (<a href="./references#CD000029-bbs2-0019" title="Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ1994;308:81-106.">ATC 1994a</a>; <a href="./references#CD000029-bbs2-0021" title="Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ2002;324:71-86.">ATC 2002</a>; <a href="./references#CD000029-bbs2-0034" title="DalenJE . Aspirin to prevent heart attack and stroke: what's the right dose?American Journal of Medicine2006;119:198-202.">Dalen 2006</a>; <a href="./references#CD000029-bbs2-0054" title="PatronoC , CollerB , DalenJE , FusterV , GentM , HarkerLA , et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest1998;114:470S-88S.">Patrono 1998</a>). Lower doses of aspirin are effective for long‐term secondary stroke prevention but have not been evaluated in acute stroke. There is some (but not abundant) evidence that at least 120 mg of aspirin is needed to acetylate all circulating platelets within a short period of time (<a href="./references#CD000029-bbs2-0053" title="PatronoC . Aspirin as an antiplatelet drug. New England Journal of Medicine1994;330:1287-94.">Patrono 1994</a>; <a href="./references#CD000029-bbs2-0067" title="vanGijnJ . Aspirin: dose and indications in modern stroke prevention. Neurologic Clinics1992;10:193-209.">van Gijn 1992</a>). There is also some experimental evidence that a dose of 160 mg to 300 mg of aspirin daily is required in the acute phase of an ischaemic cerebral or cardiac event in order to achieve rapid inhibition of thromboxane biosynthesis (<a href="./references#CD000029-bbs2-0054" title="PatronoC , CollerB , DalenJE , FusterV , GentM , HarkerLA , et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest1998;114:470S-88S.">Patrono 1998</a>; <a href="./references#CD000029-bbs2-0068" title="vanKootenF , CiabattoneG , PatronoC , SchmitzPI , vanGijnJ , KoudstaalPJ . Evidence for episodic platelet activation in acute ischaemic stroke. Stroke1994;25:278-81.">van Kooten 1994</a>; <a href="./references#CD000029-bbs2-0069" title="vanKootenF , CiabattoniG , PatronoC , DippelDW , KoudstaalPJ . Platelet activation and lipid peroxidation in patients with acute ischaemic stroke. Stroke1997;28:1557-63.">van Kooten 1997</a>). For people who can swallow, aspirin can be given by mouth. However, as many people with stroke are unable to swallow, another route may need to be used on occasions. <a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a> gave aspirin via a nasogastric tube, and <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a> gave 100 mg of the lysine salt of aspirin as a rectal suppository. </p> </section> <section id="CD000029-sec-0080"> <h3 class="title" id="CD000029-sec-0080">Other antiplatelet agents</h3> <p>The indirect comparisons of different agents in this review showed no evidence of significant heterogeneity of effect between the different agents tested, aspirin alone, ticlopidine alone, the combination of aspirin and dipyridamole. However, the data from the non‐aspirin regimens were extremely limited and such indirect comparisons are unreliable (<a href="./references#CD000029-bbs2-0019" title="Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ1994;308:81-106.">ATC 1994a</a>). The focus of current research is on comparing the effects of short‐term (30 days to three months) combination therapy with single agents, chiefly in people with TIA and minor stroke (<a href="./references#CD000029-bbs2-0029" title="WangY , WangY , ZhaoX , LiuL , WangD , WangC , CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New England Journal of Medicine2013;369:11-9. [DOI: 10.1056/NEJMoa1215340]">CHANCE 2013</a>; <a href="./references#CD000029-bbs2-0055" title="POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. New England Journal of Medicine2018;379:215-25.">POINT</a>; <a href="./references#CD000029-bbs2-0015" title="BathP . Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke (TARDIS). www.controlled-trials.com/ISRCTN47823388 (first received 24 October 2008). ">TARDIS</a>); these regimens are the subject of a separate review (<a href="./references#CD000029-bbs2-0050" title="NaqviIA , KamalAK , Rehman HNaqvi IA, KamalAK , Rehman H. Multiple versus fewer antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack. Cochrane Database of Systematic Reviews2020;8(8):CD009716. [DOI: 10.1002/14651858.CD009716.pub2]">Naqvi 2020</a>). In this update, loading with clopidogrel as compared to maintenance (and placebo) demonstrated no discernible benefit on preventing recurrent stroke (<a href="./references#CD000029-bbs2-0011" title="ZhaoY , YangW , TanZ , WangW , XiaoW , ZengJ , et al. Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial. Stroke and Vascular Neurology2017;2:e000072. ">Zhao 2017</a>). </p> </section> <section id="CD000029-sec-0081"> <h3 class="title" id="CD000029-sec-0081">Combination of aspirin with anticoagulants</h3> <p>Another question that remains unanswered is whether the addition of low‐dose subcutaneous heparin to aspirin could further reduce the risk of DVT and PE without unduly increasing the risk of intracranial and extracranial haemorrhage. One systematic review of the randomised trials of anticoagulants in acute myocardial infarction showed that the addition of IV or subcutaneous heparin did not add worthwhile extra benefit to the use of antiplatelet therapy alone (<a href="./references#CD000029-bbs2-0032" title="CollinsR , MacMahonS , FlatherM , BaigentC , RemviqL , MortensenS , et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic review of randomised trials. BMJ1996;313:652-9.">Collins 1996</a>). However, the addition of low‐dose subcutaneous heparin to aspirin might be more effective in acute stroke. The only trial that provided a direct randomised comparison of aspirin with aspirin plus low‐dose heparin was <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>, yet the available data did not provide conclusive evidence that the combination was more effective than aspirin alone. The question of whether or not to add low‐dose heparin to aspirin can, therefore, only be answered reliably by a further, much larger trial that randomly allocates participants to aspirin or aspirin plus low‐dose subcutaneous heparin. Symptomatic PE (and ICH) are infrequent in people with ischaemic stroke. Therefore, any proposed trial would need to include several 10s of 1000s of participants in order to provide reliable evidence on the size of any difference in the effects of these two antithrombotic regimens. </p> </section> <section id="CD000029-sec-0082"> <h3 class="title" id="CD000029-sec-0082">Time window for benefit from aspirin</h3> <p>There was clear evidence of net benefit when aspirin therapy was started within 48 hours of stroke onset. A more detailed meta‐analysis based on individual participant data from <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a> and <a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a> showed no clear evidence that the benefit declined with increasing time from stroke onset up to 48 hours (<a href="./references#CD000029-bbs2-0030" title="ChenZM , SandercockP , PanHC , CounsellC , CollinsR , LiuLS , et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40,000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. On behalf of the CAST and IST Collaborative Groups. Stroke2000;31:1240-9.">Chen 2000</a>). The evidence on the effects of starting treatment at more than 48 hours and within 14 days of onset was extremely limited in this review. However, taken with the data from the Antithrombotic Trialists Collaboration, the evidence is very strongly suggestive that starting after 48 hours but within 14 days of onset and continuing long term is highly likely to be of net benefit (<a href="./references#CD000029-bbs2-0021" title="Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ2002;324:71-86.">ATC 2002</a>). </p> </section> <section id="CD000029-sec-0083"> <h3 class="title" id="CD000029-sec-0083">Interaction with thrombolytic therapy</h3> <p>Thrombolytic therapy for acute ischaemic stroke within 4.5 hours of symptom onset has received regulatory approval (or is recommended in guidelines) in many places, and is the subject of ongoing research. Since antiplatelet and thrombolytic therapy can cause serious bleeding, it is important to assess the evidence for any interaction between the two agents. The subject is dealt with in some detail in the Cochrane systematic review of thrombolytic therapy (<a href="./references#CD000029-bbs2-0071" title="WardlawJM , MurrayV , BergeE , delZoppoGJ . Thrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD000213. [DOI: 10.1002/14651858.CD000213.pub3]">Wardlaw 2014</a>). The interaction between thrombolytic drugs and antithrombotic drugs given simultaneously (or the latter very soon after the former) was only tested by random allocation in <a href="./references#CD000029-bbs2-0006" title="Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet1995;346:1509-14. ">MAST‐I 1995</a>, which therefore provides the only truly valid evidence. In <a href="./references#CD000029-bbs2-0006" title="Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet1995;346:1509-14. ">MAST‐I 1995</a>, there was a clinically important adverse interaction between aspirin and streptokinase when given simultaneously, resulting in a substantial increase in case fatality (early and late), which was not offset by a reduction in the number of dead or dependent participants at the end of follow‐up; 28% of those allocated to streptokinase alone versus 43% of those allocated to streptokinase plus aspirin were dead by the end of follow‐up (P &lt; 0.001), and 62% were dead and 63% were dependent (versus 68% in the control group). The actual cause of the increase in early and total deaths with streptokinase and aspirin appeared largely to be due to neurological events. Aspirin with streptokinase significantly increased the number of deaths in hospital from all causes (OR 2.2, 95% CI 1.3 to 3.8), neurological causes (OR 2.0, 95% CI 1.1 to 3.7), and ICH on CT scan or at autopsy (OR 2.2, 95% CI 1.0 to 5.0) when compared with the group who received streptokinase alone. There was no difference in deaths from neurological causes without ICH, but note that more participants in the streptokinase plus aspirin group died of neurological causes without a CT scan or autopsy so they could also have had an ICH. That is, the increase in ICH with aspirin and streptokinase may be even greater. Information is also available on antithrombotic drug use in 12 other trials. The case fatality comparison was non‐significant (P values or CIs), though frequency was higher the nearer to the administration of thrombolysis the concomitant antithrombotic drug use was (OR 1.95 when all participants received antithrombotic drugs within 24 hours of thrombolysis; 1.27 when some participants received antithrombotic drugs within 24 hours; 1.21 when no participants received antithrombotic drugs within 24 hours but some thereafter; and 0.89 for no antithrombotic drugs within the first 10 to 14 days). Although these data are based mainly on non‐randomised comparisons, they do support the evidence of a clinically significant adverse interaction between the concurrent use of thrombolysis and antithrombotic drugs as found in <a href="./references#CD000029-bbs2-0006" title="Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet1995;346:1509-14. ">MAST‐I 1995</a>. This is confirmed by the ARTIS 2012 trial comparing recombinant tissue plasminogen activator (rTPA) plus IV aspirin with rTPA alone. In those with minor neurological deficits (National Institutes of Health Stroke Scale 0 to 5), treatment with alteplase compared with aspirin did not increase the likelihood of a favourable outcome at 90 days (<a href="./references#CD000029-bbs2-0005" title="KhatriP , KleindorferDO , DevlinT , SawyerRN , StarrM , MejillaJ , et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits. JAMA2018;320:156-66. ">Khatri 2018</a>).  </p> </section> <section id="CD000029-sec-0084"> <h3 class="title" id="CD000029-sec-0084">New developments</h3> <p>The concept of acute stroke (and the differentiation of stroke from TIA) is changing as people with acute cerebral ischaemia are assessed and treated increasingly earlier and more aggressively. The boundary between acute treatment and very early initiation of secondary prevention is becoming blurred, as evidenced by the <a href="./references#CD000029-bbs2-0029" title="WangY , WangY , ZhaoX , LiuL , WangD , WangC , CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New England Journal of Medicine2013;369:11-9. [DOI: 10.1056/NEJMoa1215340]">CHANCE 2013</a>,  <a href="./references#CD000029-bbs2-0055" title="POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. New England Journal of Medicine2018;379:215-25.">POINT</a>, and <a href="./references#CD000029-bbs2-0015" title="BathP . Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke (TARDIS). www.controlled-trials.com/ISRCTN47823388 (first received 24 October 2008). ">TARDIS</a> trials. There is clearly a place for further trials of more intensive antiplatelet regimens, started as soon after symptom onset as possible. However, since aspirin will remain the comparator treatment, such trials will need to be even larger than current trials if they are to produce reliable results. </p> </section> <section id="CD000029-sec-0085"> <h3 class="title" id="CD000029-sec-0085">Summary of main results</h3> <p>Two trials testing aspirin 160 mg to 300 mg once daily, started within 48 hours of onset, contributed 96% of the data. The risk of bias was low. Antiplatelet therapy with aspirin 160 mg to 300 mg daily, given orally (or by nasogastric tube or per rectum in people who cannot swallow) and started within 48 hours of onset of presumed ischaemic stroke, reduced the risk of early recurrent ischaemic stroke without a major risk of early haemorrhagic complications; long‐term outcomes were improved. </p> </section> <section id="CD000029-sec-0086"> <h3 class="title" id="CD000029-sec-0086">Overall completeness and applicability of evidence</h3> <p>We used GRADE to assess the certainty of evidence for each outcome (see <a href="./full#CD000029-tbl-0001">summary of findings Table 1</a>). Death or dependence at end of follow‐up and complete recovery from stroke were both assessed as moderate GRADE. The remaining six outcomes had very low GRADE. All outcomes received "serious" concern for indirectness of evidence because <a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a> included only participants of Chinese ethnicity and contributed almost 50% of the data in the meta‐analysis. Therefore, the results are mainly applicable to a Chinese population. The outcomes which were deemed very low were for various reasons, including inclusion of studies of high or uncertain risk or bias, showing variable results, and CIs being wide. For most outcomes, there were not enough studies included to accurately detect publication bias. However, publication bias was strongly suspected for the following outcomes: recurrent stroke during treatment period, any recurrent stroke or symptomatic ICH during treatment period, and major extra cranial haemorrhage during treatment period. </p> </section> <section id="CD000029-sec-0087"> <h3 class="title" id="CD000029-sec-0087">Quality of the evidence</h3> <p>The conclusions are based on overall good‐quality evidence, provided by two large well‐conducted studies. The overall risk of bias was low. </p> </section> <section id="CD000029-sec-0088"> <h3 class="title" id="CD000029-sec-0088">Potential biases in the review process</h3> <p>The review could be subject to publication bias as only published studies were included and, therefore, we may not have identified unpublished studies, or studies where there was no published abstract in English. We attempted to reduce publication bias by a comprehensive search strategy. In addition, we attempted to contact authors to obtain original data and query methodology where it was unclear; however, not all authors responded (<a href="./references#CD000029-bbs2-0005" title="KhatriP , KleindorferDO , DevlinT , SawyerRN , StarrM , MejillaJ , et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits. JAMA2018;320:156-66. ">Khatri 2018</a>; <a href="./references#CD000029-bbs2-0009" title="TurpieAG , DobkinB , McKennaR . A trial of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 1983.001.6.188)1983. ">Turpie 1983</a>; <a href="./references#CD000029-bbs2-0011" title="ZhaoY , YangW , TanZ , WangW , XiaoW , ZengJ , et al. Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial. Stroke and Vascular Neurology2017;2:e000072. ">Zhao 2017</a>). This resulted in the study methodology of one study in particular being unclear, and so we were unable to assess the risk of bias (<a href="./references#CD000029-bbs2-0009" title="TurpieAG , DobkinB , McKennaR . A trial of ticlopidine, an antiplatelet agent, for acute cerebral infarction. Guildford: Sanofi Winthrop (Sanofi internal report 1983.001.6.188)1983. ">Turpie 1983</a>). </p> </section> <section id="CD000029-sec-0089"> <h3 class="title" id="CD000029-sec-0089">Agreements and disagreements with other studies or reviews</h3> <p>We are unaware of any recently published reviews with which we can draw comparison.</p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000029-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/urn:x-wiley:14651858:media:CD000029:CD000029-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Flow diagram." data-id="CD000029-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_t/tCD000029-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/full#CD000029-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000029-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/urn:x-wiley:14651858:media:CD000029:CD000029-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD000029-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_t/tCD000029-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/full#CD000029-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000029-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/urn:x-wiley:14651858:media:CD000029:CD000029-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000029-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_t/tCD000029-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/full#CD000029-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000029-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/urn:x-wiley:14651858:media:CD000029:CD000029-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Antiplatelet agent versus control in acute presumed ischaemic stroke, outcome: 1.1 Death or dependence at end of follow‐up." data-id="CD000029-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_t/tCD000029-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antiplatelet agent versus control in acute presumed ischaemic stroke, outcome: 1.1 Death or dependence at end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/full#CD000029-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000029-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/urn:x-wiley:14651858:media:CD000029:CD000029-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Antiplatelet agent versus control in acute presumed ischaemic stroke, outcome: 1.2 Deaths from all causes during treatment period." data-id="CD000029-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_t/tCD000029-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antiplatelet agent versus control in acute presumed ischaemic stroke, outcome: 1.2 Deaths from all causes during treatment period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/full#CD000029-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000029-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/urn:x-wiley:14651858:media:CD000029:CD000029-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 1: Death or dependence at end of follow‐up" data-id="CD000029-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_t/tCD000029-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 1: Death or dependence at end of follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/references#CD000029-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000029-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/urn:x-wiley:14651858:media:CD000029:CD000029-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 2: Deaths from any cause during treatment period" data-id="CD000029-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_t/tCD000029-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 2: Deaths from any cause during treatment period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/references#CD000029-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000029-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/urn:x-wiley:14651858:media:CD000029:CD000029-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 3: Deaths from any cause during follow‐up" data-id="CD000029-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_t/tCD000029-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 3: Deaths from any cause during follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/references#CD000029-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000029-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/urn:x-wiley:14651858:media:CD000029:CD000029-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 4: Deep venous thrombosis during treatment period" data-id="CD000029-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_t/tCD000029-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 4: Deep venous thrombosis during treatment period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/references#CD000029-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000029-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/urn:x-wiley:14651858:media:CD000029:CD000029-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 5: Pulmonary embolism during treatment period" data-id="CD000029-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_t/tCD000029-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 5: Pulmonary embolism during treatment period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/references#CD000029-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000029-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/urn:x-wiley:14651858:media:CD000029:CD000029-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 6: Recurrent ischaemic/unknown stroke during treatment period" data-id="CD000029-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_t/tCD000029-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 6: Recurrent ischaemic/unknown stroke during treatment period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/references#CD000029-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000029-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/urn:x-wiley:14651858:media:CD000029:CD000029-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 7: Symptomatic intracranial haemorrhage during treatment period" data-id="CD000029-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_t/tCD000029-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 7: Symptomatic intracranial haemorrhage during treatment period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/references#CD000029-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000029-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/urn:x-wiley:14651858:media:CD000029:CD000029-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 8: Recurrent stroke/intracranial haemorrhage during treatment period" data-id="CD000029-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_t/tCD000029-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 8: Recurrent stroke/intracranial haemorrhage during treatment period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/references#CD000029-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000029-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/urn:x-wiley:14651858:media:CD000029:CD000029-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 9: Major extracranial haemorrhage during treatment period" data-id="CD000029-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_t/tCD000029-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 9: Major extracranial haemorrhage during treatment period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/references#CD000029-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000029-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/urn:x-wiley:14651858:media:CD000029:CD000029-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 10: Complete recovery from stroke (post hoc)" data-id="CD000029-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_t/tCD000029-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Antiplatelet drug versus control in acute presumed ischaemic stroke, Outcome 10: Complete recovery from stroke (post hoc) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/references#CD000029-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/media/CDSR/CD000029/image_n/nCD000029-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD000029-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antiplatelet drug compared to control in acute presumed ischaemic stroke for acute ischaemic stroke</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Antiplatelet drug compared to control in acute presumed ischaemic stroke for acute ischaemic stroke</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> acute ischaemic stroke<br/><b>Setting:</b> secondary care<br/><b>Intervention:</b> antiplatelet drug<br/><b>Comparison:</b> control in acute presumed ischaemic stroke </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with control in acute presumed ischaemic stroke</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with antiplatelet drug</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Death or dependence</b> at end of follow‐up (primary outcome) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>42,034<br/>(7 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 0.95</b><br/>(0.91 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 fewer per 1000<br/>(23 fewer to 2 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Death from any cause</b> during follow‐up </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>41,929<br/>(10 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 0.93</b><br/>(0.87 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 fewer per 1000<br/>(15 fewer to 2 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pulmonary embolism</b> during treatment period </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>41,042<br/>(7 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,e,f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 0.71</b><br/>(0.53 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 fewer per 1000<br/>(2 fewer to 0 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Recurrent ischaemic/unknown stroke</b> during treatment period </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>41,652<br/>(9 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 0.79</b><br/>(0.70 to 0.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 fewer per 1000<br/>(9 fewer to 4 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Symptomatic intracranial haemorrhage</b> during treatment period </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>41,652<br/>(9 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c,h,i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 1.18</b><br/>(0.97 to 1.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 more per 1000<br/>(0 fewer to 4 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Major extracranial haemorrhage</b> during treatment period </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>41,042<br/>(7 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,e,i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 1.69</b><br/>(1.35 to 2.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 more per 1000<br/>(2 more to 6 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Complete recovery from stroke</b> (post hoc) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>40,541<br/>(2 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Peto OR 1.06</b><br/>(1.01 to 1.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 more per 1000<br/>(2 more to 21 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>Peto</b> <b>OR:</b> Peto odds ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>The CAST study included only participants of Chinese ethnicity and contributed almost 50% of the data in the meta‐analysis. Therefore, the results are mainly applicable to a Chinese population.<br/><sup>b</sup>Death or dependence is the primary outcome measure for the majority of acute stroke intervention trials.<br/><sup>c</sup>Two studies were at high risk of bias, for one study there was no information on risk of bias, and for one study the risk of bias was unclear.<br/><sup>d</sup>Studies showed variable results (some increased, reduced or no change in the event). Therefore, results were not consistent between studies, although there was overlap in the confidence intervals and heterogeneity was low (I<sup>2</sup> &lt; 25%).<br/><sup>e</sup>One study was at high risk of bias, one study was at unclear risk of bias, and for one study information on risk of bias was not available.<br/><sup>f</sup>The analysis was based on two small studies and the confidence intervals were wide.<br/><sup>g</sup>Deep vein thrombosis and pulmonary embolism are important complications following acute stroke, but secondary to death or dependence.<br/><sup>h</sup>Recurrent stroke and symptomatic intra‐ or extra‐cranial haemorrhage were a commonly reported outcome measures but are secondary to death or dependence.<br/><sup>i</sup>The confidence intervals were wide, but data were from two large studies.<br/><sup>j</sup>Complete recovery from stroke is an important outcome, reported in the two largest trials in this review, but remains secondary to death or dependence which is the most commonly reported outcome measure. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Antiplatelet drug compared to control in acute presumed ischaemic stroke for acute ischaemic stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/full#CD000029-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000029-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Absolute risk reductions of aspirin treatment in acute stroke</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control event rate<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of events avoided<sup>b</sup> </b> </p> <p><b>(per 1000 people treated (95% CI))</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>NNTB or NNTH<sup>b</sup> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death or dependence at end of follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (3 to 23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTB 79 (43 to 400)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deaths from all causes during follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (2 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTB 108 (66 to 436)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pulmonary embolism during treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (0 to 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTB 693 (427 to 6700)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent ischaemic/unknown stroke during treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (4 to 10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTB 140 (104 to 248)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symptomatic intracranial haemorrhage during treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−2 (i.e. 2 extra) (−4 to 0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTH 574 (254 to 126,010)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any recurrent stroke/intracranial haemorrhage during treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (1 to 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTB 200 (123 to 868)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major extracranial haemorrhage during treatment period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−4 (i.e. 4 extra) (−7 to −2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTH 245 (153 to 481)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Complete recovery from stroke (post hoc)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (2 to 21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NNTB 89 (49 to 523)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>CI: confidence interval; NNTB: number needed to treat for an additional beneficial outcome; NNTH: number needed to treat for an additional harmful outcome. </p> <p><sup>a</sup>Estimated from the mean of the control event rate in the two largest trials (<a href="./references#CD000029-bbs2-0001" title="CAST (Chinese Acute Stroke Trial) Collaborative Group. A randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet1997;349:1641-9. ">CAST 1997</a>; <a href="./references#CD000029-bbs2-0004" title="International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet1997;349:1569-81. ">IST 1997</a>).<br/><sup>b</sup>Estimated by applying the Peto odds ratio for the outcome for studies of aspirin. Calculator is available at: <a href="https://www.dcn.ed.ac.uk/csrg/entity/entity_NNT2.asp" target="_blank">www.dcn.ed.ac.uk/csrg/entity/entity_NNT2.asp</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Absolute risk reductions of aspirin treatment in acute stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/full#CD000029-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000029-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antiplatelet drug versus control in acute presumed ischaemic stroke</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Death or dependence at end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.91, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Aspirin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.91, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 PF‐03049423 versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.58, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Clopidogrel loading dose versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.45, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Deaths from any cause during treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.85, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Aspirin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41291</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.85, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Aspirin plus dipyridamole versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.43, 4.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Ticlopidine versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.01, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Deaths from any cause during follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41929</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Aspirin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.87, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Aspirin plus dipyridamole versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.43, 4.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Ticlopidine versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.02, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 PF‐03049423 versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [0.74, 4.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Deep venous thrombosis during treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.36, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Aspirin plus dipyridamole versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.13, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Ticlopidine versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [0.72, 7.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Pulmonary embolism during treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41042</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.53, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Aspirin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40850</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.53, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Aspirin plus dipyridamole versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.39 [0.15, 372.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 Ticlopidine versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Recurrent ischaemic/unknown stroke during treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.70, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Aspirin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.69, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Aspirin plus dipyridamole versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 Ticlopidine versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.4 Clopidogrel loading dose versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.59, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Symptomatic intracranial haemorrhage during treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.97, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Aspirin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.96, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Aspirin plus dipyridamole versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.14, 7.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Ticlopidine versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [0.36, 20.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.4 Clopidogrel loading dose versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.14, 7.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Recurrent stroke/intracranial haemorrhage during treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41042</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.79, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Aspirin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40850</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.79, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Aspirin plus dipyridamole versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.14, 7.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 Ticlopidine versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [0.36, 20.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Major extracranial haemorrhage during treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41042</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.35, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Aspirin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40850</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.35, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Aspirin plus dipyridamole versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 Ticlopidine versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Complete recovery from stroke (post hoc) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [1.01, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Aspirin versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [1.01, 1.11]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antiplatelet drug versus control in acute presumed ischaemic stroke</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000029.pub4/references#CD000029-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000029.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD000029-note-0012">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD000029-note-0047">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000029-note-0067">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD000029-note-0042">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD000029-note-0037">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD000029-note-0062">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD000029-note-0022">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD000029-note-0032">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD000029-note-0027">Português</a> </li> <li class="section-language"> <a class="" href="ro#CD000029-note-0068">Română</a> </li> <li class="section-language"> <a class="" href="ru#CD000029-note-0017">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD000029-note-0057">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD000029-note-0052">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000029\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000029\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000029\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000029\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000029\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000029\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000029\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000029\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000029\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000029\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000029\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000029\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000029\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000029\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000029\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000029\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000029\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000029\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000029.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000029.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000029.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000029.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000029.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715874832"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000029.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715874837"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000029.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d91c2d85a9368',t:'MTc0MDcxNTg3NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 